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MUSCLE MASS AND IMMUNE FUNCTION IN THE SENIOR HORSE 
 
Senior horses (≥15 years) represent up to one-third of the global equine population, 
and the proportion of old horses (≥20 years) in the U.S. has been steadily increasing. Aging 
is associated with a loss of skeletal muscle mass in horses, and while age-related muscle 
loss is comparingly well characterized in humans, little is currently known concerning 
underlying mechanisms, adverse outcomes, or the prevalence of low muscle mass in senior 
horses. One factor proposed to play a role in the development of age-related muscle atrophy 
in humans is inflamm-aging, a low-grade inflammation that affects elderly people and that 
has also been demonstrated in horses; however, the relationship between inflamm-aging 
and muscle mass in horses is currently unclear. Besides the development of inflamm-aging, 
the equine immune system is known to undergo various additional changes with advancing 
age. Concerning alterations in immune cell function, however, most studies thus far have 
concentrated on the adaptive immune system, while the effect of aging on innate immune 
cells, such as monocytes, is less understood.  
The overarching goals of this dissertation were therefore 1) to improve our 
understanding of low muscle mass in senior horses in terms of prevalence, risk factors and 
adverse outcomes using a survey, 2) to create a muscle atrophy scoring system for horses, 
3) to determine associations between low-grade inflammation and muscle mass in horses, 
and 4) to characterize monocyte function in old horses.  
To determine the prevalence, risk factors for, and consequences of low muscle mass 
in senior horses, a U.S. wide survey with owners of horses aged ≥15 years was conducted. 
Almost 3000 individuals provided data on their senior horse in which the prevalence of 
low muscle mass was found to be 17.2%. Risk factors for low muscle mass identified in 
multi-variable regression were advancing age, male sex (gelding), osteoarthritis of the leg 
joints, pituitary pars intermedia dysfunction (PPID) and primary use type. In two-thirds of 
the horses with low muscle mass, either the ability to work, and/or welfare related aspects 
were impaired based on the owners’ observations. This study further provided insights into 
the primary use (e.g., retired, semi-retired, pleasure riding or competition riding) and the 
exercise regimen of the surveyed horses. 
To facilitate the study of muscle mass, a muscle atrophy scoring system (MASS) 
was developed and tested in 38 horses. The scoring system was based on visual assessment 
of muscle mass and muscle palpation, and the scale ranged from 1 (no atrophy; normal 
muscle mass) to 4 (severe atrophy). Inter-rater agreement results were in the good to 
excellent range for ratings of the back, neck, and hind regions, but were poor for the 
abdominal region. Muscle atrophy scores of the neck, back and hind region were  higher 
in horse groups in which atrophy is commonly observed, i.e., older, and PPID-positive 
horses, suggesting that the MASS may be a reliable tool for muscle atrophy assessment in 
the neck, back and hind region of horses, especially senior horses.  
Relationships between circulating pro- and anti-inflammatory markers and muscle 
mass indicators were explored in 22 healthy horses of varying age (2-31 years). Muscle 
atrophy scores, estimated fat-free mass, and serum creatinine levels were used as muscle 
     
 
mass indicators and no significant associations between these parameters and the 
inflammatory markers were found; although trends for a positive association between hind 
region muscle atrophy scores and two of the markers were identified.  
Lastly, the effect of age on monocyte inflammatory and phagocytic function was 
studied. Monocyte E. coli phagocytosis capacity and pro-inflammatory cytokine gene 
expression responses to lipopolysaccharide (LPS) stimulation were compared between 
young (4-6 years of age) and old (>20 years of age) horses, and the results suggest that 
monocyte phagocytosis capacity and the IL-1β (a pro-inflammatory cytokine) response to 
LPS may be altered by aging in horses.  
The findings of this dissertation provide first insights into muscle atrophy 
outcomes, risk factors, as well as potential mechanisms underlying muscle atrophy in 
senior horses. In addition, the results of this dissertation add to our understanding of age-
related changes in the immune system of the horse. The MASS developed in this 
dissertation might serve equine practitioners and horse owners in identifying and 
monitoring muscle atrophy in horses. 
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  LITERATURE REVIEW 
 Introduction 
Horses can achieve a lifespan of over 40 years1, however, once a horse reaches the 
age of 15 years it is commonly considered old1,2 and horses aged ≥30 years are generally 
considered very old1. In the U.S., the proportion of older horses (≥20 years of age) has been 
steadily increasing3 and old horses (≥15 years of age; also referred to as senior hereafter) 
have been estimated to represent up to one third of the global equine population1. In 
accordance with the increasing proportion of older horses, an increase in the percentage of 
senior horses presented at equine referral hospitals has been reported4-6, and anecdotal 
evidence suggests that more sophisticated veterinary care for aging horses has been 
sought7. Combined with the fact that aging is an important risk factor for a variety of 
medical conditions in horses1, such as pituitary pars intermedia dysfunction (PPID)8, 
recurrent airway obstruction (RAO)9, senile retinopathy10, and strangulating lipoma11, 
these data illustrate the importance of equine geriatric medicine and the relevance of 
research on the aging horse and aging-associated pathologies. 
While our understanding of certain age-related diseases, changes in physiology, 
body composition, and the immune system of aging horses has improved since the first 
book on equine geriatric medicine was published in 2006 (“Equine Geriatric Medicine and 
Surgery”6), much is still to be learned about the aging horse. Information is particularly 
limited regarding the types of health problems affecting senior horses, and factors that can 
influence senior horse health, such as management12. To date, only two larger-scale cross-
sectional studies have been conducted to provide insights into senior horse management 
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and health problems2,12-14. As these studies were conducted in Australia2,14 and in the 
U.K.12,13, data on health and management of senior horses in other countries, including the 
U.S., are currently particularly sparse. Thus, to gain insights into U.S. senior horse health 
and management, a nation-wide survey was conducted, and findings relating to primary 
horse use, exercise management, and low muscle mass in senior horses are reported on in 
Chapter 2.  
Besides the current lack of information on senior horse management and health, 
relatively little is currently known concerning changes in immune function in old horses, 
and our understanding of  conditions such as loss of muscle mass with advancing age is 
limited. These subjects are comparably well researched in humans. Therefore, the 
following sections provide a brief overview of findings from human studies concerning 1) 
age-related loss of muscle mass, 2) age-related changes in the immune system with special 
focus on low-grade inflammation and monocyte function, and 3) associations between 
inflammation and muscle atrophy. In addition, an overview of research conducted in horses 
on these topics is provided and gaps in the literature are highlighted which are addressed 
by Chapters 2-5 of this dissertation.  
 Age-related loss of skeletal muscle mass  
In humans, aging is associated with a loss of skeletal muscle mass15-17. Muscle mass 
starts to gradually decline at ~40 years of age with more rapid losses observed in 
individuals ≥70 years of age18. Besides a decline in muscle mass, reductions in muscle 
strength are also observed in the elderly, which appear to occur at a faster rate than muscle 
mass losses19. In addition, skeletal muscle undergoes structural changes with advancing 
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age which are considered to contribute to the reductions in muscle strength beyond what 
can be attributed to loss of muscle quantity19. These microscopic and macroscopic 
alterations in the architecture and composition of muscle tissue are often referred to as 
changes in “muscle quality”20 and comprise, e.g., intramuscular lipid accumulation21. 
Clinically, the age-related loss of muscle function and mass is termed sarcopenia, 
which is derived from the Greek words “sarx” (flesh) and “penia” (poverty/loss)17. The 
European Working Group on Sarcopenia in Older People (EWGSOP) proposed a definition 
based on which sarcopenia is probable in individuals with low muscle strength, is 
confirmed in persons with low muscle strength and low muscle quality or mass, and is 
severe in those with additional low physical performance.20 Sarcopenia can further be 
classified as primary (i.e., if age is the sole identifiable reason for sarcopenia), or 
secondary, if other, or additional causes are present, such as inadequate physical activity, 
inadequate nutrition, or disease20.  
The mechanisms underlying sarcopenia are complex and currently still 
incompletely understood18. Factors considered to be involved in the loss of muscle mass 
with aging include the denervation of muscle fibers and a disbalance in muscle protein 
synthesis and degradation22. Inflammatory cytokines have been proposed as one factor 
contributing to increased muscle protein degradation22 and the relationship between 
inflammatory mediators and muscle mass in the elderly is reviewed in section 1.4 of this 
introduction.  
Low muscle mass has been associated with various adverse outcomes in people. 
For example, low fat free mass (FFM, an indicator of muscle mass) at hospital admission 
was found associated with longer hospitalization23, and very low muscle mass in elderly 
4 
 
people was found associated with physical disability and functional impairment24. In 
addition, an accelerated loss of whole-body FFM and appendicular (arm and leg) muscle 
mass was identified as a risk factor for all-cause mortality in elderly individuals.25,26 
In senior horses, loss of skeletal muscle mass has been described as well. For 
example, McGowan et al.27 reported epaxial muscle atrophy in 31.5% of 325 veterinary 
examined horses aged ≥15 years27, and in a cross-sectional survey study conducted in the 
U.K., owners reported muscle loss in 19.5% of 918 horses aged ≥15 years13. In this later 
study, muscle loss was the most frequently reported clinical sign of a list of 21 items13. 
Besides loss of muscle mass, owners also reported the development of a sway back 
(10.3%), and loss of muscle tone (23.9%)13, which might represent advanced epaxial 
muscle atrophy7,8, and an early sign of muscle atrophy, respectively. In those horses aged 
≥30 years (n= 87), the prevalence of owner-reported muscle loss, sway back, and loss of 
muscle tone was heightened compared to the population of ≥15 year old horses, amounting 
to 44.8 %, 28.7%, and 55.2%, respectively28. These results suggest an age-related increase 
in muscle atrophy in senior horses. This theory is further supported by the findings of a 
study in 42 horses aged 18-29 years in which a negative correlation between estimated 
FFM and age was documented 29. Interestingly, in a study investigating unfit Standardbred 
mares, higher FFM was found in old (≥20 years of age) compared to young adult (4-8 years 
of age) horses; although, because muscle mass was not measured in these animals over 
time, it is unclear if muscle loss had occurred in individuals of the old group30.  
In addition to reports of muscle loss in senior horses, changes in muscle 
composition and mTOR signaling have been described. In the aforementioned study in 
Standardbreds, gluteus medius samples of old mares comprised significantly lower 
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percentages of type I and type IIa fibers, and a higher percentage of type IIx fibers, than 
samples of young adult horses30. In a study in Quarter Horses, however, the opposite was 
found, with a lower percentage of type IIx fibers and a higher percentage of type I fibers 
in gluteus medius samples of old (17-25 years of age) compared to young (1.8 ± 0.1 years) 
horses31. This study further described lower mitochondrial density in triceps brachii 
samples and lower cytchrome-c oxidase activity in gluteus medius and triceps brachii 
samples of the old compared to the young group31. Wagner et al. 32 examined activation of 
components of the anabolic mTOR pathway in gluteus medius samples of adult (7-14 
years) and old (22-26 years) horses of mixed breed and found no difference between the 
age groups in phosphorylation of Akt, rpS6, or 4EBP1, but identified diminished S6K1 
phosphorylation in samples of the old group. The authors suggested that this finding may 
be indicative of low muscle protein synthesis rates in old horses; however whole-body 
protein synthesis was studied as well and found to be unaffected by age32.  
Pituitary pars intermedia dysfunction (PPID), an endocrinopathy common in senior 
horses33, may represent one source of secondary (i.e., not attributable to aging alone) 
muscle loss in old horses. PPID is a neurodegenerative disorder characterized by loss of 
dopaminergic inhibition of the pars intermedia of the pituitary gland33, which leads to 
elevated production of pro-opiomelanocortin (POMC), and the peptides and hormones 
derived from POMC (e.g., adrenocorticotropic hormone [ACTH], β-endorphin and α-
melanocyte stimulating hormone)8,33. Muscle atrophy is an important clinical sign 
associated with PPID8, and a higher frequency of epaxial muscle atrophy was demonstrated 
in PPID-affected horses compared to controls 27. At the micro and macroscopic levels, 
horses with PPID appear to have atrophy of type IIa and type IIb fibers, type IIb fiber loss, 
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and larger intra-myofiber lipid droplets in gluteus medius samples than age-matched 
controls34. PPID-positive horses were further shown to have higher mRNA levels of muscle 
RING finger 1 (MuRF1), a proteolysis markers, in longissimus dorsi samples compared to 
controls35. However, in a preceding study, no difference between PPID-positive and 
control horses was found regarding MuRF1 protein abundance in gluteus medius 
samples36. This latter study moreover reported no difference in abundance or 
phosphorylation of further protein degradation regulatory factors or of protein synthesis 
regulatory factors when PPID-positive and control horses were comapred36.  
Overall, senior horses appear to be affected by muscle atrophy, similar to the age-
related loss of muscle mass observed in elderly people. While the pathology of sarcopenia 
is comparably well characterized in elderly people, less is understood about the 
mechanisms underlying muscle atrophy in senior horses and the implications of low muscle 
mass for the senior horse. In addition, while the cross-sectional survey study conducted in 
the U.K. provides first insights into the prevalence of muscle atrophy in senior horses13, 
data on the frequency of muscle loss or low muscle mass in senior horses residing in other 
countries is currently lacking. Chapter 2 of this dissertation therefore investigates risk 
factors for, adverse effects of, and the prevalence of low muscle mass in U.S. horses aged 
≥15 years.  
One potential reason for the limited information on muscle atrophy and low muscle 
mass in senior horses may be the lack of a simple, reliable, and inexpensive tool for whole-
body muscle mass assessment in horses. FFM estimation by D2O dilution37 is currently 
considered the ‘gold standard’ technique for muscle mass quantification in live horses; 
however, this method is expensive and technically challenging. A simpler technique is 
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FFM assessment via bioimpedance spectroscopy38,39; however, this technique also requires 
expert knowledge and specialized equipment. FFM may also be estimated using an 
ultrasound-based technique29, although this method may be compromised by limited 
accuracy29,40 and requires, besides access to an ultrasound machine, also experience with 
ultrasonography. More recently 3D scanning has been proposed as a method to determine 
changes in muscle mass in horses41. While this body volume-based method showed 
promising results with regard to time requirements, accuracy, and repeatability, it is limited 
by the lack of an option to separate body fat from muscle mass, and may therefore only be 
useful in body-fat stable horses and for measurement of muscle mass changes over time41.  
In humans, the ‘gold standard’ technique for body composition assessment is 
hydrostatic weighing. Unfortunately, this method is impractical for the horse given their 
size and the requirement of whole-body submersion under water42. Other techniques 
available for muscle mass assessment in humans, such as computed tomography (CT), 
magnetic resonance imaging (MRI), and Dual-energy X-ray absorptiometry (DEXA), 
have, to the authors knowledge, not been explored for muscle mass quantification in horses, 
likely due to the cost of these techniques for large animals.  
Thus, there is currently a critical need for an inexpensive tool that permits 
straightforward and reliable assessment of muscle mass and muscle atrophy in horses. The 
development of such a tool is described in Chapter 3.   
 Age-related changes in the immune system  
With advancing age, the immune system undergoes various changes, often referred 
to as immunosenescence. In humans, hallmarks of immunosenescence include a decline in 
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the number of naïve cells in peripheral blood with a concomitant increase in the proportion 
of memory cells, and the development of a low-grade inflammation43, commonly referred 
to as inflamm-aging; a term coined by Franceschi et al. in 200044.  
Inflamm-aging is characterized by a 2-4 fold increase in circulating pro-
inflammatory cytokines and acute phase proteins such as IL-6 and CRP, respectively45. In 
addition, a heightened production of pro-inflammatory cytokines by in vitro-stimulated 
immune cells has been described45.  
Elevated levels of circulating inflammatory mediators have been associated with 
morbidity and mortality in the elderly. For example, high TNFα levels have been associated 
with generalized atherosclerosis and dementia in centenarians46, and in a group of elderly 
individuals (aged ≥65 years) higher CRP levels at baseline were identified as a risk factor 
for coronary heart disease (i.e., coronary death or myocardial infarction)47. Elevated levels 
of circulating inflammatory mediators have moreover been associated with components of 
sarcopenia in the elderly48-50, and these associations are described in more detail in section 
1.4. of this introductory chapter. Lastly, higher circulating IL-6 and CRP levels have been 
shown related to mortality in older individuals51,52.  
Identifying the sources of inflamm-aging is an area of active research in the field 
of gerontology. Proposed origins include genetic susceptibility, obesity, the composition 
of the gut microbiome, gut permeability, dysregulated immune cells, and chronic 
infections53; but also a disbalance in the production and clearance of cell debris, misplaced, 
or altered molecules, leading to a persistent pro-inflammatory activation of innate immune 
cells 53,54.  
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In horses, inflamm-aging has been demonstrated as well, and comprises an age-
related increase in serum TNFα protein levels and whole-blood TNFα, IL-15, IL-1β and 
IL-18 mRNA levels55. In addition, age-related increases in the proportion of lymphocytes 
and monocytes responding with IFNγ and TNFα production to in vitro stimulation have 
been elucidated29,55,56, as well as elevated basal IL-6, IL-8, and IFNγ gene expressions in 
peripheral blood mononuclear cells (PBMCs) of old horses57, and age-related increases in 
the ratio of pro- to anti-inflammatory cytokines (TNFα/IL-10 and IL-6/IL-10) in PBMCs57. 
Comparably few studies have reported no age-related increases in inflammatory markers 
in horses32.   
To the authors knowledge, only two studies provided insights into potential 
mechanisms underlying the pro-inflammatory state observed in the senior horse. Adams et 
al.56 assessed the effect of body fat percent on inflammatory status in old horses and found 
associations between changes in body fat and circulating TNFα levels, as well as between 
changes in body fat and the proportion of immune cells responding with pro-inflammatory 
cytokine production to stimulation. Adams et al.55 further demonstrated that lymphocytes 
of old horses mainly remained in the parent generation when stimulated to proliferate, and 
that a large proportion of these non-dividing lymphocytes produced IFNy.  
Besides the development of a pro-inflammatory state with advancing age, further 
changes in the immune system of horses and people have been described. In both humans58 
and equine59, age-related changes occurring in the adaptive immune system have been 
researched more extensively, while the effect of aging on innate immunity is currently less 
understood. When comparing research efforts in horses and in humans, however, much 
less is currently known about innate immune function in senior horses.  
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Regarding changes in the function of the equine innate immune system, Miller et 
al.59 showed reduced myeloperoxidase levels in plasma and lower numbers of circulating 
monocytes in old compared to adult horses 59. Significantly lower monocyte counts have 
also been described in old compared to young ponies60. McFarlane et al.61 studied 
neutrophil functions in old horses and found no difference between young adult and old 
animals in neutrophil phagocytosis capacity or oxidative burst activity, but reported greater 
neutrophil chemotaxis in old horses.  
In elderly people, various age-related changes in the function of monocytes have 
been described. These include e.g., increases in basal TNFα production, increased TNFα 
production in response to stimulation with bacterial membrane component 
lipopolysaccharide (LPS)62, as well as reduced phagocytosis62,63 and efferocytosis 
(clearance of apoptotic cells)63. Changes in monocyte functions can have important 
implications for the immune response to vaccination64 and infection62. In addition, reduced 
efferocytosis has been suggested as a factor contributing to inflamm-aging in the 
elderly63,65.  
In horses, comparably little is currently known about age-related changes in 
monocyte function. Adams et al.56 demonstrated an elevated percentage of TNFα 
producing monocytes in old compared to young horses after in vitro monocyte stimulation 
with PMA/ionomycin. Hansen et al.66 found non-significant trends to an age-related 
increase pro-inflammatory cytokine gene expression in LPS-stimulated PBMCs, and 
McFarlane et al.57 showed an elevated release of TNFα from LPS stimulated PBMCs in 
old compared to adult horses. While these studies provide first insights into monocyte 
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function in old horses, a comprehensive examination of potential alterations in monocyte 
functions in senior horses has, to date, not been undertaken.  
In conclusion, as observed in elderly people, senior horses develop a low-grade pro-
inflammatory state (inflamm-aging). While age-associated changes in the adaptive immune 
system are well characterized, less is currently known about the effect of aging on the 
innate immune system. In particular with regard to monocytes in old horses, little is known 
regarding changes in function with advancing age. The phagocytic and inflammatory 
functions of monocytes from old horses were therefore characterized in Chapter 5. Chapter 
4 includes further characterization of inflamm-aging in horses, but mainly focusses on 
associations between inflammatory makers and muscle mass. A brief review of the 
relationship between inflammation and changes in muscle mass in the elderly is provided 
in the following section.  
 Associations between inflammation and muscle mass in the elderly 
Multiple studies in elderly people found relationships between circulating 
inflammatory mediators (cytokines and acute phase proteins) and muscle mass or strength. 
Schaap et al.50 showed e.g., that elevated TNFα serum levels were associated with a greater 
5-year loss of thigh muscle cross-sectional area and hand grip strength in a group of weight-
stable elderly individuals. In addition, associations between high serum CRP and IL-6 
levels and an elevated risk of losing over 40% of hand grip strength during a 3-year period  
have been described 49. In a meta-analysis of 16 studies, serum CRP was found to be 
significantly higher in sarcopenic individuals compared to controls, while significant 
differences in serum TNFα or IL-6 levels between the groups were not observed48.  
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Besides these correlative associations seen in multiple studies, a direct involvement 
of inflammation in the pathophysiology of sarcopenia has been proposed22,49,67,68, but is 
currently not confirmed67-69; especially for low-grade inflammation68. Pathways suggested 
to potentially play a role in sarcopenia include e.g., pro-inflammatory cytokine-mediated 
impairment of satellite cell function68, and TNFα and IL-6-mediated increases in muscle 
protein degradation through enhanced activation of the ubiquitin-proteasome pathway22,69. 
In addition, a novel concept has been proposed in which dysfunctional muscle tissue 
induces a chronic inflammatory response, which then, in turn, impairs skeletal muscle 
function, leading to cyclic exacerbation of inflammation and muscle dysfunction67; 
however this model requires formal interrogation. In addition, while many studies suggest 
an involvement of inflammation in age-related muscle atrophy, not all studies have found 
a relationship between elevated inflammatory markers and loss of muscle mass. In a recent 
study by Ito et al. 70 lower levels of serum TNFα were observed in elderly individuals with 
low muscle mass compared to those with normal muscle mass.  
In horses, potential relationships between inflammatory markers and muscle mass 
have been investigated in only a few studies. Siard-Altman et al. 29 found a positive 
correlation between serum IL-6 level and estimated FFM in an age-adjusted and in an 
unadjusted model. In this study29, associations between estimated FFM and serum CRP, as 
well as further inflammatory markers (e.g., IL-10, IL-1β, TNFα, IL-6 and IFNγ gene 
expression in PBMCs post in vitro stimulation) were explored as well, but no significant 
associations were found.  
As a considerable body of research in humans suggests a relationship between 
inflammatory mediators and loss of muscle mass and strength, further exploration of 
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potential associations between muscle mass and inflammatory mediators in horses is 
warranted. The study described in Chapter 4 of this dissertation provides some insights into 
associations between circulating inflammatory markers and muscle mass indicators in 
horses.  
 Dissertation goals and hypotheses 
While age-related loss of muscle mass is well characterized in humans, much less 
is currently known about loss of muscle mass in senior horses. Therefore, it was the goal 
of the study described in Chapter 2 to estimate the prevalence of low muscle mass in U.S. 
senior horses (≥15 years) and to identify risk factors for, and adverse outcomes of, low 
muscle mass in this age group.  
Rapid, frequent, and reliable muscle mass assessment in horses is currently 
hampered by the lack of an inexpensive, simple, and reliable tool. Therefore, it was the 
goal of the study described in Chapter 3 to develop and evaluate a muscle atrophy scoring 
system for horses.  
In elderly people, relationships between inflammatory mediators and sarcopenia 
have been described and a role of inflammation in the pathogenesis of age-related muscle 
loss has been proposed. In horses, the relationship between inflammation and muscle mass 
is currently poorly understood. Therefore, it was the goal of the study described in Chapter 
4 to explore associations between circulating inflammatory mediators and muscle mass 
indicators in horses. The hypotheses of this study were that 1) circulating inflammatory 
mediators are associated with muscle mass indicators, 2) circulating inflammatory 
mediator levels are higher in older horses, and 3) muscle mass is lower in older horses.  
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Changes in the function of monocytes can have implications for the immune 
response to vaccination and infection. While age-associated alterations in the function of 
monocytes are comparably well characterized in elderly people, little is currently known 
about the function of monocytes in old horses. Therefore, it was the goal of the study 
described in Chapter 5 to assess if aging alters the phagocytosis capacity and inflammatory 
function of monocytes in horses. The hypothesis of this study was that monocyte pro-
inflammatory cytokine responses to LPS are higher in old than in young adult horses, and 






 PRIMARY USE, EXERCISE MANAGEMENT, AND MUSCLE MASS IN U.S. SENIOR 
HORSES 
 Summary 
Background: Information on the management and health of U.S. senior horses (≥15 years 
of age) is currently limited. 
Objectives: Provide information on 1) primary use of U.S. of senior horses, 2) reasons and 
risk factors for horse retirement, 3) exercise management, 4) the prevalence of low muscle 
mass, 5) risk factors for, and owner-perceived consequences of, low muscle mass.   
Study design: U.S. cross-sectional study.   
Methods: 2717 questionnaires from owners of U.S. resident senior horses (≥15 years of 
age) were analyzed using descriptive and inferential statistics.  
Results: The most frequently reported primary uses were pleasure riding/driving (38.5%) 
and full retirement (39.8%); use for competition and semi-retirement (i.e., retired from 
riding/driving but performing some structured exercise) were less common (10.2% and 
11.5%, respectively). Most horses (61.5%) were retired between 15-24 years of age and 
the main reason for retirement was health problems. Age, female sex, and Thoroughbred 
breed were risk factors for retirement. Horses used for competition exercised more 
frequently and intensely than horses used for pleasure riding/driving. The prevalence of 
low muscle mass in all surveyed horses was 17.2% (95%CI= 15.5-18.6). In those affected 
by low muscle mass, the ability to work and welfare-related aspects were commonly 
perceived to be impaired. Various risk factors for low muscle mass were identified.   
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Main limitations: Potential response, recall and sampling bias. Causal relationships cannot 
be established.  
Conclusions: A large proportion of horses were fully retired although exercise into old age 
may provide health benefits, as seen e.g., in elderly people. Senior horses were mainly 
retired for health problems and characterizing these problems may aid in extending their 
work/active life. Low muscle mass affects welfare and the ability to work in senior horses 
and identification of prevention and treatment strategies is therefore warranted.  
Keywords: senior horse; management; retirement; low muscle mass; survey   
Full reference: Herbst A. C., Coleman M. C., Macon E. L., et al. Primary use, exercise 
management and muscle mass in U.S. senior horses. Equine Veterinary Journal 2021, 
accepted with revisions 
 
 Introduction 
Although senior horses (≥15 years of age) likely represent up to one-third of the 
global equine population,1 information on their management and health is currently 
limited; especially for those residing in the U.S. Studies focusing on older U.S. horses 
conducted thus far have either been of small scale,71 have concentrated on hospital 
populations,4,72 or focused on horse-human relationships,73 veterinary care decision-
making,73,74 or burdens of caring for older horses74. In other countries, a few large-scale 
surveys have been undertaken to obtain information on senior horse health and 
management.2,12-14 
Senior horses may fulfill a variety of roles ranging from athletic partners to 
companions, with some being fully retired from exercise.2,12,71,73-75 For U.S. senior horses, 
17 
 
data on main roles/uses and exercise management is currently sparse, with few studies 
reporting on these topics.71,73,74 Both the primary role/use and exercise management likely 
have important implications for health and welfare. In humans for example, physical 
activity and fitness into old age provide various health benefits.76 One of these benefits is 
the reduction of age-related loss of muscle mass, strength, and function (sarcopenia),22,77 a 
condition that is prevalent in elderly people,78 and has been associated with disability and 
increased mortality.25,26,79-81 Senior horses appear to be affected by loss of muscle mass as 
well,13,27 although the prevalence of low muscle mass in U.S. senior horses is currently 
unknown, as are potential adverse outcomes.  
The overall goal of this project was therefore to improve the understanding of U.S. 
senior horse management and health through a nationwide survey. The specific objectives 
of the first part of this exploratory study were to provide information on 1) primary use, 2) 
reasons and risk factors for horse retirement, 3) exercise management, 4) prevalence of low 
muscle and 5) risk factors for, and owner-perceived consequences of, low muscle mass in 
U.S. senior horses.  
 Methods 
2.3.1 Survey design 
A three-stream online questionnaire comprising 128 questions, including follow-up 
questions, was created (Qualtrics 2020, Provo, UT; Figure 2.1). Data from the third stream 
is described in this article. This stream focused on a senior horse (≥15 years) that the 
participant had owned for at least 1 year. The horse’s barn name was displayed throughout 
the survey as a reminder of the horse in question. The survey questions were of multiple or 
18 
 
single choice type. Some questions contained an option for an open-ended answer, e.g., if 
the answer choice was “other”. Because the survey was administered during the COVID-
19 pandemic in fall 2020, it included questions about adjustments made to the horse’s usual 
management due to the pandemic. The complete survey questionnaire is provided in 
supplemental file 2.1.  
2.3.2 Pilot testing, participation eligibility and survey distribution 
The survey was pilot tested by persons in the researchers’ network and the feedback 
was used to refine the questionnaire. The final anonymous survey was distributed through 
a press release (supplemental file 2.2) sent to horse-related publications and through social 
media channels (e.g., Facebook). The press release addressed the purpose of the survey, 
participation eligibility criteria, and the option to enter a raffle. Prizes were horse feed or 
treats. Email addresses for raffle participation were recorded detached from the survey, 
precluding matching of survey responses with personal information. 
Individuals aged ≥18 years who owned at least 1 horse or pony that resided in the 
U.S. were eligible to participate. The project was approved by the University of Kentucky 
Institutional Review Board (IRB). Informed consent to participate was obtained on the first 
page of the survey. Responses were limited to one survey per owner. The survey was online 
from October 15th to November 21st, 2020.   
2.3.3 Data preprocessing 
Surveys were examined for 1) description of ineligible equids (e.g., mules), 2) 
description of >1 horse/ survey, 3) entry of a “non-horse name” to be displayed throughout 
the survey as a reminder of the horse described, 4) current ownership of zero horses. These 
surveys were excluded from analysis (supplemental Figure 2.3). Responses were also 
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reviewed for obvious errors, apparent from contradictory responses. These were either 
removed from the data set or corrected if the information provided was sufficient. Some 
answer choices were combined into larger plausible groups to reduce the number of 
categories. Open ended responses were reviewed and either 1) assigned to groups 
predefined as answer choices in the questionnaire, 2) assigned to biologically plausible 
groups newly defined based on themes of the text entries, or 3) were excluded from analysis 
if the response could not be confidently assigned to one of the defined groups. Responses 
indicating that the participant was unsure about the answer, or preferred not to answer, 
were excluded. Supplemental file 2.4 contains the R code (R version 4.0.4) used for data 
preprocessing. 
2.3.4 Statistical analysis  
R82 (version 4.0.4) was used for data analysis and illustration, with a P ≤0.05 
considered significant. 
2.3.4.1 Descriptive statistics 
Proportions were computed for frequency counts of nominal or ordinal variables. 
Arithmetic means ± SD, medians, and ranges were computed for interval variables. Horse 
age and years of senior horse ownership were treated as interval variables though they were 
recorded on scales caped at 40 years (with 40= ≥40) and 35 years (with 35= ≥35), 
respectively, due to the question format (responses were selected on a finite number line). 
Selection of maximal values was rare (n= 8/2137 for horse age; n= 8/2628 for years of 




2.3.4.2 Inferential statistics  
A confidence interval (95%-CI) was calculated for the estimated prevalence of low 
muscle mass. Linear regression was used to determine associations between horse age 
(explanatory variable) and exercise intensity or frequency (response variable) in two 
separate models. Differences in horse age, exercise frequency or intensity between horses 
of different primary use types were assessed using ANOVA (F-test) or Student’s t-test. 
Ordinal exercise frequency and intensity variables were coded as interval variables for 
parametric analysis.  
Risk factors for retirement and low muscle mass were assessed using logistic 
regression (F-test). Univariable association tests were performed for all recorded variables 
that were plausible biologically relevant explanatory variables. The univariable tested 
parameters are listed in supplemental Table 2.5 (retirement) and supplemental Table 2.6 
(low muscle mass). ANOVA was applied to explanatory variables with >2 levels and was 
followed by Tukey tests for pairwise comparisons if main effects were significant.  The 
subsets of univariable tested predictors to be included in multivariable risk factor analysis 
were identified using best subsets,83 with Akaike informative criterion (AIC) selected as 
the evaluation criteria. Natural logarithm-odds ratios (ln-OR) and corresponding ln-95%-
CI were back-transformed to ORs and 95%-CIs for reporting. 
Where relevant, acceptable homoscedasticity and normal distribution of residuals 
was confirmed using diagnostic plots. Models did not include interaction terms. Missing 
or excluded data were treated as missing; data was not imputed. As the response rate varied 




2.4.1 Owner demographics 
Of 2927 total surveys started, 2717 stream-3 surveys were eligible for analysis 
(supplemental Figure 2.3). Thirty-five (34.8) percent of respondents were equine 
professionals (defined as having earned >50% of their income/wage in the horse industry 
at some point), whilst 65.2% were ‘hobby horse owners’ based on this above definition (n= 
2194). The majority had owned horses for over 10 years (n= 1968/2241). At the time of 
the survey, 20.9% owned 1 horse, 25.0% owned 2 horses, and 54.0% owned ≥3 horses of 
any age (n= 2717). 
2.4.2 Horse demographics 
The mean duration of ownership was 12.9 ± 7.3 years (median= 13 years; range= 
1-35 years, with 35= ≥35 years; n= 2628). Exact age was known for 2137 horses, and the 
mean age was 22.2 ± 4.9 years (median= 21 years; range= 15-40 years, with 40= ≥40 
years). Most horses were geldings (60.4%), followed by mares (38.3%); only 1.3% were 
stallions (n= 2613). Represented breeds were Quarter Horse (27.9%; mean age= 22.7 ± 4.9 
years), Thoroughbred (15.6%; mean age= 21.3 ± 4.6 years), Paint (8.7%; mean age= 20.7 
± 3.9 years), Warmblood (6.2%; mean age= 20.8 ± 3.9 years), Arabian (6.0%; mean age= 
24.0 ± 5.2 years), and gaited breeds (5.1%; mean age= 22.4 ± 5.2 years); 30.6% (mean 
age= 22.6 ± 5.1 years) were considered in the category ‘other breeds’ comprising mixed 
breeds and breeds with a representation <3% (n= 2565 total responses to question). Most 
horses were kept on pasture (Figure 2.2). Southeastern states had the highest representation 
(n= 980/2607; supplemental Figure 2.7) and most horses resided in Kentucky (n= 
379/2607). At least one horse was represented from every U.S. state. 
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2.4.3 Primary use 
The horses were predominantly used for pleasure riding/driving (38.5%) or were 
retired from all structured exercise (39.8%); only 11.5% were semi-retired (i.e., performing 
some structured exercise, but retired from riding/driving) and 10.2% were used for 
competition riding or driving/training for competition (n= 2401). Fully retired horses were 
significantly older than horses of other use types (P<0.001; Figure 2.3A), and the use type-
profiles differed between age categories with “pleasure riding/driving” being the most 
frequent use type for horses 15-24 years old, and “fully retired” for those ≥25 years of age 
(Figure 2.3B). Few respondents indicated that their horses’ primary use would have been 
different in the absence of the COVID-19 pandemic (n= 139/2489). Most of these horses 
would have been used for competition riding or driving/training for competition (n= 
93/121). 
2.4.4 Reasons and risk factors for retirement  
Table 2.1 summarizes the frequencies of horses retired at various ages (1- ≥30 
years) and the reasons. These included both horse-centered rationales, such as insufficient 
performance for competition, and owner centered motives such as “[o]wner health 
challenges”. Whilst the main reason for retiring horses at a young age (1-9 years) was to 
change the horses’ career to breeding, older horses (>10 years) were most frequently retired 
for horse health related reasons (Table 2.1). Most horses (n= 568/924) were retired between 
15 and 24 years of age (Table 2.1).  
Age, sex, and breed were significantly associated with the odds of retirement in the 
univariable (supplemental Table 2.5) and multivariable analyses (Table 2.2). Multivariable 
results indicated that, based on the estimated OR, every one-year increase in age was 
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associated with a 20% increase in odds of retirement (Table 2.2). Mares had 90% higher 
odds of retirement than geldings (Table 2.2). Thoroughbreds had higher odds of retirement 
than Arabians, Paints, Quarter Horses, and the group of ‘other’ breeds (Table 2.2). 
2.4.5 Exercise management 
Most non-retired horses exercised (e.g., riding, lunging, hand-walking [for semi-
retired horses]) between 1-2 times per week (31.6%), followed by 3-4 times (28.8%), less 
than once a week (24.8%), 5 times per week (10.8%), 6-7 times per week (3.7%) and over 
7 times per week (i.e., multiple times per day; 0.2%) (n= 1394; Figure 2.4A). Age was 
negatively associated with exercise frequency (Figure 2.4A), and horses used for 
competition exercised more frequently than horses used for pleasure riding/driving, or 
semi-retired horses (Figure 2.4C). 
Horses used for competition exercised predominantly at a moderate intensity (walk, 
trot, canter; 66.7%), followed by high intensity (galloping, high level competition riding or 
training; 28.2%) and low-to-moderate intensity (walk and trot; 5.1%) (n= 234). Horses 
used for pleasure riding/driving also exercised most frequently at a moderate intensity 
(50.4%), followed, however, by low-to-moderate (36.2%), low (mainly walking; 12.4%) 
and high (1%) (n= 879). Age was negatively associated with exercise intensity (Figure 
2.4B), and the exercise intensity was significantly higher in horses used for competition 
than in those used for pleasure riding/driving (Figure 2.4D). Semi-retired horses performed 
various types of structured exercise including hand-walking (65%), lunging (49.3%), 
stretching (31.0%), occasional pleasure rides (25.9%), horse-walker exercise (6.2%), and 
other exercises (4.4%; e.g., ground driving and liberty work) (n=274). 
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Twelve percent of respondents indicated that their horses’ exercise frequency 
would have been different in the absence of the COVID-19 pandemic, while 3.8% reported 
that their horse’s exercise intensity would have been different (n= 2489). Most of these 
horses would have exercised 3-4 times per week (n= 100/252), and at a high intensity (n= 
44/83). 
2.4.6 Prevalence of low muscle mass 
The prevalence of owner-reported low muscle mass (defined as a sign of declined health) 
was 17.2% (95%-CI= 15.7 - 18.7; n= 410/2390). The low muscle mass was most frequently 
perceived as extremely obvious in the back and hip regions (Figure 2.5). 
2.4.7 Implications of, and risk factors for, low muscle mass 
Owners of horses with low muscle mass indicated that this affected the horses’ ability 
to work (39.5%), to “get up” after lying down (30.5%), the interaction with other horses 
(16.8%), and daily activities of walking in the pasture (14.7%) (n= 380). Thirty-four 
percent of owners (n=128/380) reported no adverse effects of their horse’s low muscle 
mass.   
In univariable analysis, the odds of owner-reported low muscle mass were 
associated with age, breed, sex, dental disorder, osteoarthritis of the leg joints (leg-OA), 
pituitary pars intermedia dysfunction (PPID) and primary use, but not with housing type 
during summer and fall 2020 (supplemental Table 2.6). The final multivariable model 
comprised age, sex, leg-OA, PPID, and primary use, and all parameters were significantly 
associated with the odds of low muscle mass (Table 2.3). Based on the estimated odds-
ratio mares had 30% lower odds of low muscle mass than geldings (Table 3). Horses with 
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PPID and leg-OA had 60% and 50% higher odds of low muscle mass than unaffected 
horses, respectively (Table 2.3). Retired horses had higher odds of low muscle mass than 
those used for competition or pleasure riding/driving (Table 2.3), and semi-retired horses 
had higher odds than horses used for competition (Table 2.3). With every one-year increase 
in age, the odds of low muscle mass increased by 10% (Table 2.3; Figure 2.6).  
 Discussion  
Many characteristics of the surveyed horses resembled those of senior horses 
described in similar studies conducted in other countries; e.g., the sex distribution, median 
age, and median duration of ownership were similar.2,12 In contrast to these previous 
studies, in which Thoroughbreds/ Thoroughbred-crosses were the most common breeds,2,12 
Quarter Horses were most numerous in this present study, reflecting that this breed is  also 
the most represented in the general U.S. horse population.84 Ponies were common in 
previous studies,2,12 but had a low representation in this present work (<3%); possibly in 
part due to slightly divergent definitions of a pony (i.e., pony= pony breed with ≤148 cm 
wither height [present work] vs. pony= all pony breeds and pony-horse crosses with <144 
cm wither height2). 
Most surveyed horses were used for pleasure riding/driving or were fully retired. 
These use categories were also among the most common in previous surveys of elderly 
U.S. horses (aged ≥20 years),73,74 which supports our findings and suggests that pleasure 
riding/driving and retirement are like some of the main use types of senior horses in the 




“Horse health problems” was the most prevalent reason for retiring a horse from 
structured exercise. Further research elucidating the types of health problems leading to 
retirement would be beneficial, as this information could be used to develop prevention 
strategies that may permit extending a horse’s work/active life. A prolonged work/active 
life may not only be desired by owners but is also likely to provide health benefits to the 
horse. In elderly people, a myriad of exercise-associated health benefits have been 
described,22,76,77 and structured exercise might therefore similarly help preserve and 
improve overall health in senior horses. 
Frequency, duration, and intensity of the exercise should, however, be appropriate 
and should not exceed limitations posed by the horse’s health status or physiological 
capacities. The ability to thermoregulate during exercise, maximal aerobic capacity, and 
maximal heart rate, for example, appear to be diminished in older mares,85,86 suggesting 
that higher-intensity exercise protocols used in young or middle-aged horses may be 
inappropriate for older horses.87 While these considerations are especially important for 
horses used for higher level competition, they are also relevant for horses of other use types 
with high workloads, or for those affected by conditions that may further reduce their 
ability to exercise. Information on the maximal amount of exercise (i.e., the combination 
of maximal frequency, intensity and duration) that will not place senior horses at a risk of 
adverse outcomes is currently limited, especially across horse breeds, sexes, fitness levels, 
disciplines, and health statuses. The same is true for information on exercises that provide 
health benefits for senior horses. To make informed recommendations on health-preserving 
or health-improving exercise protocols for individual horses, data on both topics would be 
very useful.  
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This study suggests that 1 in 6 U.S. senior horses (17.2%, 95%CI= 15.7 - 18.7) are 
affected by low muscle mass. The true prevalence is, however, likely higher. This is 
expected because while horse owners reported to be confident in the recognition of muscle 
atrophy,75 muscle loss is often not recognized until severe,88 and senior horse owners 
appear to under-recognize/report health problems in their animals;1 possibly because they 
consider them part of the normal aging process.13  
Most owners of horses with low muscle mass indicated that their horse’s ability to 
work, or welfare-related aspects were affected by the low muscle mass. This supports that 
prevention and treatment strategies should be developed, possibly including exercise 
prescriptions which were found successful in elderly people.22,77,78 In addition, these data 
suggest that routine monitoring may be advisable, for example using the recently developed 
equine muscle atrophy scoring system (MASS).40 The risk factor profile established in this 
present study may further assist veterinarians and horse owners/caretakers to identify 
animals at risk of low muscle mass to be selected for close monitoring.  
When interpreting the results of this work, the limitations inherent to the study design 
should be considered. For example, the degree to which the data was affected by response 
bias, including recall bias, is unclear. These biases may have occurred due to respondent’s 
variable knowledge about their horse, their interpretation of the questions, and inquiry of 
historical data. In addition, selection bias is possible due to limitation of the survey to 
individuals with internet access, the channels through which the survey was advertised, 
and the incentive to participate (raffle prize). Lastly, while the response rate in this survey 
was relatively high, sampling bias has likely occurred, with participation skewed towards 
Kentucky, possibly because the University of Kentucky advertised the survey, leading to a 
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heightened participation by employees, students, and loyal alumni. While the findings of 
this study may therefore not be generalizable to the U.S. senior horse population, the 
authors of this article believe nevertheless that this work provides valuable insights into 
U.S. senior horse management and health.  
 Conclusion 
Many senior horses were retired for health problems and characterizing these 
problems may aid in extending their work/active life. In addition, given the health benefits 
of exercise seen in elderly people, research into exercise protocols that may preserve or 
improve overall health in senior horses would be beneficial. Low muscle mass affects 
welfare and the ability to work in senior horses and research on prevention and treatment 







Table 2.1 Frequencies of horses retired at different ages and the primary reasons for retirement from all structured exercise. 















Primary reason for retirement       




























































Owner/rider not willing/able to ride 











































Percentages shown for the prevalence of reasons for retirement within an age category. Please note that the response rates for the 
questions about the age at retirement and the primary reason for retirement differed (n= 924, and n= 861, respectively), therefore the 
sample sizes indicated in the table core do not equal the sample sizes reported in the first row and first column of this table.  
a Athletic performance insufficient was defined as athletic performance insufficient to continue competition riding/driving.  
b ‘Other’ summarizes reasons provided as open-ended answers that could not be clearly assigned to any other defined category. ‘Other’ 




Table 2.2 Risk factors for retirement. 
Variable OR (95%CI) P-value 


















0.3 (0.15; 0.62) 
0.4 (0.22; 0.75) 
0.5 (0.30; 0.76) 







Abbreviation: ref., reference group. Sample size multivariable analysis: n= 1922.  
a Stallions were excluded due to low representation (n= 33). 
b P-value of main effect for breed. Categories: Arabian, Quarter Horse, Gaited Breeds, 
Paint, Thoroughbred, Warmblood, ‘Other’.  




Table 2.3 Risk factors for low muscle mass.  
Variable OR (95%CI) P-value 




































4.6 (1.66; 13.00) 
3.7 (1.23; 10.98) 
ref. 




  0.01 
 
<0.001 
Abbreviation: ref., reference group. Samples size of multivariable analysis: n= 1795.   
a Stallions were excluded due to low representation (n= 33). 
b Owner reported, veterinary diagnosed osteoarthritis of the leg joints (leg-OA). Leg-OA 
was reported to be present at the time of the survey in n= 679 and to be absent in n= 1754.  
c Owner reported, veterinary diagnosed pituitary pars intermedia dysfunction (PPID). PPID 
was reported to present at the time of the survey in n= 288 and to be absent in n= 2145. 
d P-value for main effect of primary use. Primary use was inquired for July, August, 
September 2020 (i.e., the three months prior to the survey). Categories: retired (i.e., no 
structured exercise), semi-retired (i.e., retired from riding/driving but performing some 
structured exercise), pleasure riding/driving and competition riding or driving/training for 
competition.  




Figure 2.1 Online questionnaire.  
Participants were guided through one of three streams. Stream-1 opened for individuals 
owning only younger horses (<15 years), stream-2 opened for short term (<1 year) owners 
of senior horses (≥15 years), and stream-3 opened for longer term (≥1 year) owners of 
senior horses. The “General 1” section contained general questions for all three streams 
and questions specific to individual streams. Stream-3 was divided into 12 sections with 
questions covering general information (3 sections), horse use and exercise management, 
the aging process of horses and management of an aging horse (Aging), and further aspects 
of horse management and health. Participants had the option to exit stream-3 after the 
health care section. Stream-3 responses are reported on in this manuscript. PPID= Pituitary 









Figure 2.2 Housing of surveyed senior horses between fall 2019 and fall 2020.  
The housing category under which horses spent most of their time was inquired.  Housing categories (from left to right): 1. Drylot only, 
2. Outdoors only, 3. Pasture only, 4. Stall with <12h a day on drylot, 5. Stall with <12h a day on pasture, 6. Stall with ≥12h a day on 
drylot, 7. Stall with ≥12h a day on pasture, 8. Stall/other indoor facility only. “Outdoors” represents outdoor housing with insufficient 
data provided for assignment to the pasture or drylot category. Response rates were n=2433 (fall 2019), n= 2433 (winter 2019/2020), 
n= 2427 (spring 2020), n= 2421 (summer 2020), n= 2384 (fall 2020). Few respondents (n=32/2576) indicated that their horses would 












Figure 2.3 Primary uses of surveyed senior horses during July, August, and September 
2020.  
A Boxplots illustrating age differences between horses of different primary use type. 
Primary uses: retired (i.e., no structured exercise), semi-retired (i.e., retired from 
riding/driving but performing some structured exercise), pleasure riding/driving and 
competition riding or driving/training for competition. Triangle: mean age. Estimated mean 
differences (EMD) in age shown with corresponding 95%-CI in parenthesis. Significance 








Figure 2.4 Exercise frequencies and intensities in surveyed senior horses during July, 
August, and September 2020.  
Average exercise (e.g., riding, lunging, hand-walking [for semi-retired horses]) frequency 
and intensity during a typical session was inquired. Scatterplots include point jitter. A 
Association between exercise frequency and age (n= 1155). Data of horses used for 
competition, pleasure riding/driving and semi-retired horses shown. Regression line 
(black) with standard error (grey) and regression coefficient (β) with 95%-CI in 
parenthesis. Frequencies (<1 to >7 times per week) coded as numbers (1-6; 1= <1) for 
analysis. B Association between exercise intensity and age (n= 918). Intensity was only 
inquired for horses used for pleasure riding/driving or competition. Intensities: low (mainly 
walking), low-moderate (walk and trot only), moderate (walk, trot, canter), high (galloping, 
high level competition riding or training). Regression line (black) with standard error (grey) 
and regression coefficient (β) with 95%-CI in parenthesis. Intensities (low-high) coded as 
numbers (1-4, 1= Low) for analysis. C Box plots for differences in exercise frequency 
between horses of different use type (n= 1155). Frequencies defined and coded as for A.  
Estimated mean-differences (EMD) in frequency shown with corresponding 95%-CIs in 
parenthesis. Triangles: mean frequency. When the model was adjusted for age, differences 
remained: Competition vs. Pleasure= EMD(95%-CI)= 1.02(0.83; 1.21), P<0.001; 
Competition vs. Semi-retired= EMD(95%CI)= 1.28 (1.05; 1.52), P<0.001; Pleasure vs. 
Semi-retired= EMD(95%CI)= 0.26(0.08; 0.45), P=0.002. D Box plots for differences in 
exercise intensity between horses used for competition and pleasure riding/driving (n= 
1113). Intensities were defined and coded as described under B. Triangles: mean intensity. 
EMD displayed with corresponding 95%-CIs in parenthesis. Differences remained in the 
age-adjusted model: EMD(95%-CI)= 0.81(0.71; 0.92), P<0.001. Significance level for C 












Figure 2.5 Degree of low muscle mass visibility in various body regions of affected horses.  






Figure 2.6 Percentage of horses with low muscle mass by horse age. Age data was available 
for n= 300 horses with owner-reported low muscle mass and n= 1654 without. Horses aged 





 DEVELOPMENT AND EVALUATION OF A MUSCLE ATROPHY SCORING SYSTEM 
(MASS) FOR HORSES  
 Abstract 
Loss of skeletal muscle mass likely compromises performance and welfare in horses 
and thus routine monitoring would be valuable. Currently available methods to assess 
muscle mass require expert knowledge and are often expensive. To provide a simple 
method, a muscle atrophy scoring system (MASS) was created and tested by three 
evaluators (raters) in 38 horses of varying age, breed, and health status. Inter-rater 
agreement on atrophy scores was in the good-to-excellent range for ratings of the neck 
(ICC= 0.62), back (ICC= 0.62) and hind (ICC= 0.76) regions, but was poor for the 
abdominal region (ICC= 0.29). Due to this low agreement, the abdominal region was 
excluded from further analysis. Associations between muscle atrophy scores and age, 
pituitary pars intermedia dysfunction (PPID) status, and body composition indicators, 
including weight and estimated fat-free mass (FFM), were examined. Weight was inversely 
associated with neck, back and hind muscle atrophy scores (β= -0.008, β= -0.008, β= -
0.009, respectively; all P<0.001), but estimated FFM was not associated with muscle 
atrophy scores at any region (P>0.05). Age was positively related to neck (β= 0.030, 
P<0.01), back (β= 0.037, P<0.001) and hind (β= 0.040, P<0.001) muscle atrophy scores. 
PPID-positive horses (n=4) had higher muscle atrophy scores than PPID-negative horses 
(n=23), even after adjusting for age (P<0.05). This data suggests that neck, back and hind 
region evaluations by individual raters likely have acceptable reliability. In addition, these 
findings support further evaluation of the potential benefits of the MASS to identify and 
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Full reference: Herbst, A. C., Johnson, M. G., Gammons, H., et al., Development and 
evaluation of a muscle atrophy scoring system (MASS) for horses. Journal of Equine 
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 Introduction 
Muscle atrophy is a clinical sign associated with various equine medical conditions. 
For example, horses affected by pituitary pars intermedia dysfunction (PPID) 8, equine 
motor neuron disease 89, or chronic pelvic fracture 90 often present with muscle atrophy. In 
addition, muscle loss may be observed in general in older horses 13,27,28 or due to 
malnutrition 88.  
In humans, low fat-free mass (FFM; a muscle mass indicator) was related to longer 
hospitalization 23. Accelerated loss of appendicular (arm and leg) muscle mass and FFM 
was also associated with higher mortality 25,26. In horses, loss of muscle mass is likely 
related to adverse events as well, although specific data is sparse. Valberg 88 suggested, 
however, that even minor muscle loss may affect power output and athletic performance 
in horses. In addition, a high proportion of owners of senior horses (≥15 years) with 
perceived low muscle mass reported in a survey that their horses’ ability to work (n= 
150/380) or to “get up” after lying down (n= 116/380) was affected by the low muscle 
mass91. 
Whilst severe muscle loss may be readily identified, minor progressive changes often 




available for objective whole-body muscle mass assessment in live horses include FFM 
estimation via bioimpedance spectroscopy 38,92, deuterium oxide dilution 37,92 or rump-fat 
ultrasonography 30,93, as well as  3D scanning, a body volume-based approximation 41. 
Thickness of individual muscles or muscle groups may be quantified using muscle 
ultrasonography 93,94, although measurements can have poor reproducibility as well as 
repeatability 95, and the number of muscles that can be reliably evaluated is limited. In 
addition, all the above methods require expert knowledge, are often expensive, and are 
typically not available to individual horse owners.   
In dogs and cats, simple muscle condition scoring tables have been used to assess 
muscle atrophy 96,97. To the authors’ knowledge, comparable muscle scoring systems are 
currently not available for the use in horses. The body condition scoring system is 
unsuitable, because it was developed to evaluate body fat 98, and the subjective, picture-
based muscle scoring system developed by Graham-Thiers and Kronfeld 99 lacks clear 
definitions for the muscle mass categories. A muscle scoring system with distinct category 
definitions was created by Walker et al. 100, although the goal of this system was to evaluate 
muscle development in dressage horses rather than muscle atrophy specifically. In addition, 
this system is highly detailed, and therefore potentially too time-consuming for owners to 
regularly undertake.  
The main objective of this study was therefore to create a simple muscle atrophy 
scoring system (MASS) for horses. Further objectives were to (1) assess rater agreement 
on muscle atrophy scores, (2) explore associations between atrophy scores and 
objective/semi-objective body composition indicators (weight, estimated FFM, 




atrophy scores were higher in horse groups in which atrophy is frequently observed (i.e., 
PPID-positive and older horses).  
 Methods 
3.3.1 Development of the muscle atrophy scoring system (MASS) 
The Walker et al. 100 muscle scoring system was used as a template. Terminology 
and rules for score assignment were simplified, the scoring scale was reduced, and some 
scoring regions were merged into larger areas. Various scoring criteria were modified 
based on multiple pilot trials. The final proposed MASS (Table 3.1) included criteria for 
muscle atrophy scoring in four regions: neck, abdomen, back and ‘hind’ (pelvis/hind limb 
region). The scoring scale ranged from 1 (“no atrophy”, i.e., normal muscle mass) to 4 
(“severe atrophy”), with half scores permitted (example pictures for “no” and “severe 
atrophy” in supplemental Table 3.1).  
Two scoring tables were created for each region, one for “lean” and one for 
“adipose” horses.  “Adipose” tables were similar to “lean” tables but included additional 
guidance for differentiation of muscle from subcutaneous fat to help improve score 
accuracy. Table selection criteria (“lean” vs. “adipose”) were based on the Carter et al. 101 
and Henneke et al. 98 scoring systems, so that horses with a visible crest in the neck region 
(crest score ≥2/5) and above ‘moderate’ body condition (body condition score >5/9) in the 
back, abdomen and hind regions, were evaluated using the “adipose” scoring tables for the 
respective regions (Table 3.1). Horses with lower cresty neck scores (CNS <2/5) 101 and 





Illustrations were designed for the scoring system to aid score assignment (Table 
3.1). Clarification of the terminology used is provided in supplemental Figure 3.2. 
 
3.3.2 Evaluation of the MASS 
3.3.2.1 Horses 
Twenty-nine non-pregnant mares and 9 geldings (mean age ± SD= 18.82 ± 9.87 
years, range= 2-31) were used. The horses’ body composition and muscle atrophy data are 
summarized in Table 3.2. Represented breeds were Thoroughbred (16/38), mixed breed 
(8/38), Quarter Horse (3/38), Warmblood (3/38), Standardbred (2/38), Arab (1/38), Paint 
(1/38), Tennessee Walking Horse (1/38), Rocky Mountain Horse (1/38), Spotted Saddle 
Horse (1/38), and Mustang (1/38). The horses were housed in cohorts on pasture or semi-
dry lots at the University of Kentucky Veterinary Science Department’s Maine Chance 
Farm in Lexington, Kentucky, or at the C. Oran Little Research Center in Versailles, 
Kentucky. All animals were kept idle in their paddocks and had not performed structured 
exercise for at least one year prior to this study. The horses were either maintained on a 
pasture-only diet or received complementary feed to maintain body weight. All study 
procedures were approved by the University of Kentucky Institutional Animal Care and 
Use Committee.  
3.3.2.2 Pituitary pars intermedia dysfunction (PPID) testing 
Based on basal plasma adrenocorticotropic hormone (ACTH) levels, and in 
accordance with classifications proposed by the Equine Endocrinology Group 102, horses 




50 pg/mL), or “PPID-positive” (ACTH >50 pg/mL). ACTH quantification was carried out 
in ethylenediaminetetraacetic acid (EDTA) plasma at the Cornell University Animal 
Health Diagnostic Center (Ithaca, NY) using a chemiluminescent immunometric assay 
(Immulite® 1000; Siemens, Munich, Germany), validated for equine samples 103. Testing 
was performed about 8 months prior to the start of the study, in February and March, in all 
adult horses (≥6 years, n= 30).  
3.3.2.3 Muscle atrophy, body condition, and cresty neck scoring 
Following initial training by rater A (part of the MASS development team), on 
horses not enrolled in the study, three raters (A, C and S; C and S were not part of the 
MASS development team) evaluated the horses for muscle atrophy using the MASS (Table 
3.1). For evaluation, the horses stood on an even surface and as square as could be 
reasonably achieved, with the head positioned as indicated in Table 3.1. Those who did not 
naturally adopt this head position were offered small amounts of feed to help maintain in 
the correct position. Muscle atrophy scores were recorded for the left and right side, and 
selection of a ‘lean’ vs. an ‘adipose’ scoring table was recorded for each region and side. 
BCS 98 and CNS 101 were assigned by the three raters as well, all of whom were experienced 
with the BCS and CNS scoring procedures. Half scores were permitted. Individual horses 
were judged for muscle atrophy scores, BCS and CNS on the same day by all raters.  
3.3.2.4 Morphometric measurements 
Belly girth, neck circumference and cannon bone circumference (CBC) were 
recorded to the nearest 0.10 cm using a plasticized measuring tape. All measurements were 




the point of the shoulder and the tuber coxae (point of hip) 101, on maximal exhalation. 
Neck circumference was measured at 1/2 the distance between the poll and highest part of 
the withers 104. For neck circumference measurements, the horses’ top neckline was held 
approximately parallel to the ground and the tape was applied perpendicular to the top 
neckline. CBC was measured on both front legs, approximately half-way between the most 
dorsal point of contact between the proximal phalanx and the cannon bone (third 
metacarpal bone) and the most dorsal part of the cannon bone head. For each leg, three 
measurements were taken, averaged per side, and the smaller average circumference was 
used, and is referred to as the horses CBC. To approximate across horse sizes, body 
composition indicators were divided by CBC, and the resulting ratios are termed 
“standardized” indicators. During the measurements, the horses were standing as square as 
possible on a flat even surface.  
3.3.2.5 Body weight and fat-free mass (FFM) estimation 
Body weight was recorded to the nearest pound using a digital floor scale (Tru Test 
Inc, Mineral Wells, TX), and pounds were converted to kilograms for data analysis. FFM 
was estimated using the formula: FFM= Weight (kg) – [Weight (kg) x %-body fat] 93. Body 
fat percentage was approximated using a prediction equation for empty-body fat percent 
(EBFP), where EBFP= [5.47 x RFT (cm)]+ 2.89, and RFT is ultrasonographically 
measured rump fat thickness (RFT) 105.  RFT was measured on the horses left side, at 
approximately 10 cm from the midline and 11 cm from the tailhead 105. The site was 
clipped, ethanol cleaned, the exact probe placing location was marked and ultrasound gel 
was applied. Images of the subcutaneous fat layer were recorded using a SIUI CTS-7700V 




8.2 MHz, B-gain range= 50-80). Horses were standing as square as possible on an even 
surface, and some were restrained in stocks. Six horses were excluded because they 
required sedation for ultrasonography, which was expected to affect measurement accuracy 
as horses were unable to stand balanced on all four legs for the duration of the scan. To 
further increase precision when estimating percent fat from RFT, only images with clear 
lines at the dorsal and the ventral aspect of the subcutaneous fat layer were selected (n= 
17), and RFT was re-measured in these images using the software ImageJ (core project 
version 1.X  106). Measurements were scaled to distances recorded with the ultrasound 
calipers to obtain RFT (cm) (for examples see supplemental file 3.3).    
3.3.2.6 Statistical analysis 
Analysis was performed using the statistical software R (version 4.0.4 82). Inter-
rater agreement on muscle atrophy scores, BCS and CNS was determined by computing 
intraclass correlation coefficients (ICC). Models were specified as two-way random effect, 
single-measure, agreement ICC 107, and calculated using the R package “irr” 108. For muscle 
atrophy scores, left and right-side averages were used. Resulting ICCs were categorized as 
poor (ICC <0.40), fair (ICC= 0.40-0.59), good (ICC= 0.60-0.74) and excellent (ICC= 0.75-
1.00) 109. Rater agreement on the muscle scoring table selected (“lean” vs. “adipose”)  was 
determined using Light’s Kappa 110,111 in the ‘irr’ R package 108. Kappa-based agreement 
was interpreted as slight (κ= 0.00-0.20), fair (κ= 0.21-0.40) moderate (κ= 0.41-0.60), 
substantial (κ= 0.61-.80) and almost perfect (κ= 0.81-1.00) 112. Associations between 
muscle atrophy scores and body composition indicators (i.e., estimated FFM, weight, 
morphometric measurements, BCS and CNS) were analyzed using linear mixed-effects 




side mean) were fitted as the outcome variable, body composition indicators as the fixed 
effect, and rater and horse as random effects. To explore if associations between muscle 
atrophy scores and body composition indicators differed among subgroups of horses (e.g., 
horses with high vs. low BCS), a grouping factor was included in the model, which was 
fitted as an interaction term with the body composition indicator. Significant interactions 
were identified from analysis of variance (ANOVA) tables and prompted within-subgroup 
association analysis. Associations between muscle atrophy scores and age and PPID status 
were assessed using individual and combined (age and PPID status included as fixed 
effects) linear mixed-effects models and ANOVA, with horse, rater and muscle atrophy 
scores fitted as described above.  
Data of all models was visually analyzed for acceptable homoscedasticity and 
normal distribution of residuals using residuals vs. fits plots and residual histograms, 
respectively. Marginal and conditional R2 (R2m and R2C) were calculated to describe the 
variance explained by fixed effects, and random and fixed effects, respectively 113, using 
the “Nakagawa’s R2” function (‘performance’ package 114). Linear models were calculated 
using the “lme4” 115 and “lmerTest” 116 packages. The “emmeans” package 117 was used to 
analyze trends within subgroups and for pairwise comparisons of muscle atrophy scores 
between groups of differing PPID status. Tukey’s adjustment (family confidence level= 
95%) was applied for multiple comparisons. For all other tests, results were considered 
significant at P ≤0.05.  
Muscle atrophy scores of all horses, irrespective of which scoring table (“lean” vs. 
“adipose”) was applied by individual raters, were used as one data set in the regression 




criteria were overall very similar. Some data points were missing for muscle atrophy 
scores, scoring table selection, body weight and BCS. Sample size is therefore indicated 
for all results.  
 Results 
The final MASS is provided in Table 3.1, and muscle atrophy scores assigned to the 
participating horses are summarized in Table 3.2. Neck, back, hind and abdomen atrophy 
scores were all significantly and positively correlated (P <0.001) (supplemental Figure 
3.4). Individual rater’s atrophy scores for the left and right side of any evaluation region 
differed maximally by one point. Full-point differences were recorded for one neck muscle 
atrophy evaluation (1/114 total three-rater evaluations in n= 38) and three abdominal region 
muscle atrophy ratings (3/99 total three-rater evaluations in n= 33). Half-point differences 
were recorded for neck (17/114), back (8/99), abdominal (10/99) and hind (16/114) region 
muscle atrophy ratings.  
3.4.1 Inter-rater agreement 
Inter-rater agreement results were in the excellent range for CNS and BCS (Table 
3.3). Rater agreement on the scoring table selected (“lean” vs. “adipose”) was in the 
moderate range for the neck region and in the substantial range for the hind region (Table 
3.3). Kappa analysis results indicated only random agreement on tables selected for the 
back and the abdominal regions (P>0.05; Table 3.3). Inter-rater agreement on muscle 
atrophy scores was in the good range for the neck region and the back region, in the 
excellent range for the hind region, but in the poor range for the abdominal region (Table 




this region were not included in further hypothesis testing as a significant reduction in 
power was expected.  
3.4.2 Associations between muscle atrophy scores and body composition indicators 
Table 3.4 shows the associations between muscle atrophy scores and body 
composition indicators. BCS was overall significantly and inversely associated with 
muscle atrophy scores of all three scoring regions (P <0.001; Table 3.4). When horses were 
separated into groups of lower and higher body condition (BCS ≤5 and >5, respectively), 
based on the three raters’ average BCS ratings, a significant inverse relationship between 
muscle atrophy scores and BCS remained only in the lower BCS group (Figure 3.1A-C). 
Similarly, lower CNS was overall related to higher neck atrophy scores (P= 0.01; Table 
3.4); but when horses were divided into groups of “no visible neck crest” (three-rater 
average CNS <2) and “visible crest” (three-rater average CNS ≥2), significant inverse 
associations were seen only in the lower CNS group (Figure 3.1D).  
Lower neck circumference was overall significantly associated with higher neck 
muscle atrophy scores (P <0.01; Table 3.4). When horses were classified as having “no 
palpable neck crest” (i.e., no crest) or having “a (palpable) crest”, based on the three raters 
average CNS ratings (CNS <1, CNS ≥1, respectively), a significant association between 
neck muscle atrophy scores and neck circumference was found only in the group without 
neck crest (no crest group: β= -0.086, 95% CI= -0.122, -0.050, n= 9; crest group:  β= 0.001, 
95% CI= -0.023, 0.024, n= 29, R2m/R2c= 0.41/0.69). The regression coefficient (β= -0.086) 
indicated that a 10 cm reduction in neck circumference was related to a 0.86-point increase 
in average neck atrophy score of horses in the no-crest group. Neck muscle atrophy scores 




Table 3.4), and when grouping horses based on crest palpability as above, significant 
associations between standardized neck circumference and neck atrophy scores were seen 
only in horses without crest (no crest group: β= -1.917, 95% CI= -2.650, -1.185, n=9; crest 
group; β= -0.053, 95% CI= -0.474, 0.369, n= 29, R2m/R2c= 0.43/0.69).  
Belly girth was significantly related to back atrophy scores, so that a 10 cm 
reduction in girth was associated with a 0.29-point increase in average back muscle atrophy 
scores (β= -0.029, P <0.01; Table 3.4). Standardized belly girth was also associated with 
back atrophy scores (P <0.01; Table 3.4).  
Body weight, and standardized body weight, were significantly and inversely 
associated with muscle atrophy scores of all three scoring regions (P <0.001; Table 3.4). 
Estimated FFM was not significantly associated with muscle atrophy scores of any region, 
but standardized estimated FFM was significantly associated with neck atrophy scores (P= 
0.04; Table 3.4). 
3.4.3 Relationships between muscle atrophy scores, age and PPID status 
Figures 3.2A, 3.2B and 3.2C illustrate the relationships between horse age and 
neck, back and hind muscle atrophy scores, respectively. Increasing age was significantly 
related to higher neck (P <0.01, Figure 3.2A), back (P <0.001, Figure 3.2B) and hind (P 
<0.001, Figure 3.2C) atrophy scores. The regression coefficients indicated that a 10-year 
increase in age was associated with a 0.3-point increase in average neck atrophy score (β= 
0.030; Figure 3.2A), a 0.37-point increase in average back atrophy score (β= 0.037, Figure 
3.2B) and a 0.4-point increase in average hind atrophy score (β= 0.040; Figure 3.2C). After 




0.05, R2m/R2c= 0.32/0.69), but was no longer significantly associated with back or hind 
atrophy scores (P= 0.07, R2m/R2c= 0.34/0.73; P= 0.09, R2m/R2c= 0.36/0.83, respectively). 
Based on the basal plasma ACTH levels, four horses were PPID-positive (ACTH 
mean ± SD= 100.90 ± 78.51 pg/mL), three were PPID-equivocal (ACTH mean ± SD= 
40.47 ± 7.55 pg/mL), and 23 were PPID-negative (ACTH mean ± SD= 19.52 ± 5.01 
pg/mL). The eight young horses (<6 years of age) were not tested. Neck, back and hind 
muscle atrophy scores of the horses grouped by PPID status are illustrated in Figures 3.3A, 
3.3B and 3.3C, respectively. Neck atrophy scores were estimated to be on average 1.10-
points higher in PPID-positive than in PPID-negative horses (P <0.01, 95% CI= 0.374, 
1.822), and 1.39-points higher than in untested horses (P <0.001, 95% CI= 0.567, 2.204). 
Back muscle atrophy scores were estimated to be on average 1.02-points higher in PPID-
positive horses than in PPID-negative horses (P <0.01, 95% CI= 0.209, 1.833) and 1.61-
points higher than in untested horses (P < 0.001, 95% CI= 0.702, 2.512). Back muscle 
atrophy scores were further estimated to be on average 0.59-points higher in PPID-negative 
than in untested young horses (P < 0.05, 95% CI= 0.011, 1.162). Hind muscle atrophy 
scores in PPID-positive horses were estimated to be on average 1.11-points higher than in 
negative horses (P <0.01, 95% CI= 0.288, 1.928), 1.3-points higher than in equivocal 
horses (P <0.05, 95% CI= 0.142, 2.455), and 1.72-points higher than in the young, untested 
horses (P <0.001, 95% CI= 0.792, 2.646).  
When the model was adjusted for age, neck muscle atrophy scores remained 
significantly higher in PPID-positive vs. PPID-negative horses (P= 0.01, estimated mean 
group difference (EMGD)= 0.90, 95% CI= 0.161, 1.647), however, the PPID-positive and 




1.923). Back muscle atrophy scores remained higher in PPID-positive compared to 
negative horses (P= 0.04, EMGD= 0.86, 95% CI= 0.045, 1.674), but differences between 
PPID-positive vs. untested horses, and the negative vs. untested group were no longer 
significant (P= 0.31, EMGD= 0.88, 95% CI= -0.488, 2.248; P= 0.99, EMGD= 0.02, 95% 
CI= -0.970, 1.011, respectively). Similarly, differences in hind muscle atrophy scores 
remained only for the PPID-positive compared to the negative horses (P= 0.03, EMGD = 
0.91, 95%= 0.061, 1.770), and for the PPID-positive group when compared to the equivocal 
group (P= 0.03, EMGD= 1.21, 95%= 0.081, 2.350), while differences between the PPID-
positive vs. the untested group were no longer significant (P= 0.38, EMGD= 0.92, 95%= -
0.618, 2.450).  
 Discussion 
In this study, a simple scoring system to evaluate muscle atrophy (defined as a 
decrease in muscle size below normally expected levels) in the neck, abdominal, back, and 
hind regions was developed and tested by three individuals in 38 horses. Inter-rater 
agreement on muscle atrophy scores assigned to the neck, back and hind regions was in the 
good to excellent range, but agreement on abdominal region ratings was poor. Muscle 
atrophy scores were linearly and inversely related to BCS, CNS, neck circumference, belly 
girth and body weight, but were not associated with estimated FFM. As expected, muscle 
atrophy scores were higher in PPID-positive horses when compared to negative controls 
and were positively associated with age.  
Rater agreement on neck, back and hind muscle atrophy scores was good to excellent. 




training. Similar inter-rater agreement results were reported for whole-body muscle 
condition ratings in cats and dogs 97,118, and for muscle development ratings in horses using 
the Walker et al. 100 system. A direct comparison of the results from these previous studies 
and this present work is, however, not possible, as different statistical methods and 
approaches to result interpretation were used.  
In contrast to the acceptable evaluator agreement on neck, back and hind muscle 
atrophy scores, inter-rater agreement on abdominal muscle atrophy scores was poor. This 
might be explained by the lack of visual muscle atrophy assessment criteria for evaluation 
of this region. While visual appraisal of muscles is a component of neck, back and hind 
muscle atrophy evaluation, rating of abdominal muscle atrophy is entirely based on 
subjective palpation. Walker et al. 100 reported greater inter-rater agreement on abdominal 
muscle evaluations using their muscle development scoring system. This system includes 
assessment of abdominal shape and reference to the sternum. Future adjustment of the 
MASS abdomen evaluation criteria to include visual assessment and reference to bones 
might hence improve inter-rater agreement results.  
The three raters achieved excellent inter-rater agreement for BCS and CNS, which 
exceeded ICCs reported for these fat scores in a previous study 101. BCS and CNS ICCs 
were also higher than ICCs for muscle atrophy ratings at all scoring regions except for the 
hind region, where CNS and muscle atrophy score ICCs were similar. All evaluators in this 
present study were experienced in body condition and cresty neck scoring, which might 
have contributed to the high rater agreement on BCS and CNS. Additional muscle atrophy 




As previously observed in dogs and cats 97,118,119, BCS was overall significantly 
associated with muscle atrophy scores. Interestingly, when horses were divided into 
subgroups of lower and higher body condition (BCS ≤5 and >5, respectively), muscle 
atrophy scores and BCS were only significantly and inversely related in the lower BCS 
group. This may suggest that in horses with higher BCS, muscle atrophy is independent 
from the amount of fat stored, while in leaner horses, muscle mass and fat stores are lost 
concomitantly. Further investigation is needed, however, to confirm the lack of association 
between BCS and muscle atrophy ratings in the higher BCS group, as analysis power in 
this present study might have been compromised by rater disagreement on muscle atrophy 
scores for horses in this group. This disagreement is apparent in Figures 3.1A-C, where 
regression slopes and intercepts for the higher BCS group show moderate between-rater 
variation.   
Higher neck atrophy scores were associated with lower neck circumference in horses 
without palpable neck crest, but not in horses with a crest. This difference is expected as 
neck circumference is positively correlated with CNS 101; thus, in horses with a crest, neck 
circumference is influenced by crest size, rendering it an inaccurate measurement of neck 
muscle mass. In horses without neck crest however, neck circumference might serve as an 
indicator of neck muscle volume, as the neck is mainly composed of muscle, besides the 
vertebra, the nuchal ligament, the esophagus and the trachea 120. Whether circumference-
based muscle volume accurately reflects muscle atrophy, however, is currently unclear. 
Therefore, further validation of the neck muscle atrophy scores as a measurement of muscle 




Lower belly circumference was related to higher back atrophy scores. While belly 
circumference is likely altered by loss or gain of epaxial muscle volume, the measurement 
also reflects horse size, the volume of other muscles, as well as fat, and, as suggested by 
Dugdale et al. 121, probably also gut fill. Therefore, belly circumference may not be a 
reliable indicator for muscle mass in the back region if measured at a single time point, 
even if the measurement is corrected for horse size. Hence, further investigation using a 
more accurate indicator of back muscle volume would be beneficial to evaluate if back 
atrophy scores accurately reflect muscle mass.  
Body weight was inversely associated with muscle atrophy scores. Similar 
observations were made in a study in cats in which whole-body muscle condition scores 
were correlated with weight 97. Because body weight is a measurement composed of 
multiple components such as fat weight, muscle weight, bone weight, organ weight, and 
gut fill, and it is related to horse size (e.g., larger animals are expected to have a higher 
body weight than smaller animals), it is not exactly clear what the observed relationships 
represent. It possible that body weight components other than muscle mass were relatively 
similar in horses enrolled in this study and body weight differences therefore 
predominantly reflected differences in muscle mass, but relationships between muscle 
atrophy and weight should be investigated further to better understand the observations in 
this study.  
Muscle atrophy scores were not related to estimated FFM, except for neck atrophy 
scores, which were significantly associated with body size corrected (standardized) FFM. 
There are several possible reasons for the overall lack of associations between muscle 




muscle mass, while atrophy scores were assigned to individual regions. Secondly, the 
rump-fat ultrasound-based FFM estimation method used in this present study may not be 
highly accurate. Siard-Altman et al. 29 showed for example that the agreement between 
FFM estimates obtained using the Kane et al. 105 ultrasound technique and a golden 
standard method (D2O dilution) was not very good. One possible reason for this limited 
agreement may be that rump fat thickness is measured at a location defined by exact 
measurements rather than proportional distances; as a result ultrasound probe placement is 
more cranial in shorter horses, likely affecting FFM prediction accuracy as fat cover 
decreases from tail to back 105. Lastly, it is important to consider that estimated FFM 
represents, besides muscle mass, also bone mass, viscera mass and gut fill. 
In humans 15,16 and animals 96,97,118,119, including horses 29, increasing age was found 
associated with decreasing muscle mass, or FFM. In horses specifically, Siard-Altman et 
al. 29 showed that FFM was significantly and inversely correlated  with age in horses aged 
18-29 years old. In the present study, a significant positive association between neck, back 
and hind muscle atrophy scores and age was found, suggesting that higher atrophy scores 
were assigned to older unfit horses, in which muscle atrophy would be expected. When 
adjusting the regression model for PPID status, however, relationships between age and 
muscle atrophy scores remained only for the neck region, and even this association was 
only marginally significant (P= 0.05). These findings may indicate that the relationship 
between age and muscle atrophy in unfit horses is not attributable to aging alone but may 
be influenced by health status, including PPID status, and factors such as dental 
abnormalities, which are frequently observed in senior horses 28,122 and may lead to 




Both the age-adjusted and the unadjusted model showed that PPID-positive horses 
had significantly higher neck, back, and hind muscle atrophy scores than PPID-negative 
horses. Because muscle atrophy is a clinical sign of PPID 8,34, and rates of (epaxial) muscle 
atrophy and muscle fiber atrophy and loss seem to exceed those of unaffected aged 
counterparts 27,34, the findings of this present study might indicate that the MASS correctly 
identifies horses with muscle atrophy. In addition, these findings support further evaluation 
of the potential benefits of the MASS to identify and monitor muscle atrophy in horses 
affected by PPID specifically. For this evaluation, further testing of the system in control 
and affected horses is needed, as the number of PPID-positive and equivocal horses was 
small in this study (n= 4 and n= 3, respectively). Besides the small number of PPID-positive 
horses, it should be considered that while the raters were blinded to the horses ACTH 
results, they were aware of the horses’ approximate ages and possible PPID category (e.g., 
due to presence or absence of key clinical signs such as abnormal hair coat 8,123).  This 
limitation is another important reason for the necessity to further validate the system.  
This study had several additional limitations. Firstly, enrolled horses were idle, and 
Thoroughbreds were overrepresented. Whether the scoring system is valid for horses in 
structured exercise, or in all of the distinctively different horse types and breeds, such as 
draft horses or ponies, requires further investigation. If the MASS is used in horses being 
exercised, atrophy evaluation prior to ridden exercise is recommended, as in some horses 
back dimensions increase after riding 124. Secondly, horses were evaluated for muscle 
atrophy only at a single time point. Thus, it is unclear if the scoring system will accurately 
detect (especially minor) muscle atrophy differences over time and if atrophy scores can 




Thirdly, the scoring system was created to measure ‘critical’ muscle atrophy, or more 
specifically, to quantify muscle mass that is below the normally expected levels for a horse; 
similar to the muscle condition scoring tables used in dogs and cats 97,118. Therefore, the 
scoring system is likely unsuitable to assess muscle atrophy that may occur in horses with 
above normal muscle mass, such as muscle loss in athletic horses due to detraining. For 
such evaluation, the Walker et al. 100 muscle development scoring system, or a discipline-
adjusted variation thereof, would likely be more appropriate.  Fourthly, the scoring system 
has, thus far, not been validated for reflection of true muscle atrophy as well as truly normal 
muscle mass for the ‘no atrophy’ category. A golden standard method for confirmation of 
normal muscle mass and muscle atrophy that is applicable to the general horse population 
would be needed for such validation. Lastly, while muscle atrophy scores were tested for 
associations with other possibly more objective proxies of muscle mass, such as estimated 
FFM, this study did not evaluate how accurately muscle atrophy scores reflect true muscle 
mass in the neck, abdominal, back, and hind regions. Therefore, further validation of the 
scoring system, for example by comparing pre-mortem muscle atrophy scores with actual 
muscle mass measured post-mortem, would be beneficial. 
 Conclusion 
The equine muscle atrophy scoring system (MASS) shows promise when applied to 
the neck, back and hind regions as inter-rater agreement (reliability) results were in the 
good to excellent range. Higher muscle atrophy scores were assigned to older and PPID-
positive horses, suggesting that the MASS may correctly identify horses with muscle 




muscle atrophy scores compared to actual muscle mass, and the ability of the scoring 






























Table 3.1 (continued) 
a      
aEvaluation criteria for abdominal region identical for lean and adipose horses. Atrophy 






Table 3.2 Summary of muscle atrophy scores and body composition indicators recorded in 
participating horses. 
Parameter Mean ± SD Range Sample size 
Muscle atrophy scoresa,b    
Neck 2.14 ± 0.61 1.00 - 4.00 38 
Abdomen 1.89 ± 0.49 1.33 - 3.50 33 
Back 1.95 ± 0.62 1.00 - 4.00 33 
Hind 2.22 ± 0.71 1.17 - 4.00 38 
Body condition scorec 5.12 ± 1.15 2 - 8 37 
Cresty neck scorec 1.50 ± 0.89 0 - 4 38 
Cannon bone circumference (cm) 20.07 ± 0.82 18.43 - 22.00 38 
Neck circumference (cm) 98.53 ± 7.56 80.00 - 119.50 38 
Belly girth (cm) 212.80 ± 10.98 188.70 - 236.00 38 
Body weight (kg) 552.50 ± 50.86 415.90 - 675.90 37 
FFM (kg)d 487.20 ± 27.64 414.70 – 538.00 17e 
a Atrophy score categories: 1= “no atrophy”, 2= “mild atrophy”, 3= “moderate atrophy”, 
4=   “severe atrophy”. 
b Mean ± SD and range based on three raters’ average scores, where scores were means of 
ratings recorded for the left and right side.  
c Mean ± SD and range based on three raters’ average scores. 
d Fat-free mass (FFM), was estimated using the formula: FFM= Weight (kg) – [Weight 
(kg) x (%-body fat)] 93, where %-body fat was calculated using the empty-body fat 
percent (EBFP) formula by Kane et al. 105, which is based on ultrasonographically 
measured rump fat thickness (RFT): EBFP = 5.47 x RFT + 2.89.    
e Small sample size due to rigorous selection of clear ultrasound images and exclusion of 







Table 3.3 Inter-rater agreement results for muscle atrophy scores, BCS and CNS. 
 
Abbreviations: MASS N., muscle atrophy scoring system neck region. MASS B., muscle atrophy scoring system back region. MASS 
H., muscle atrophy scoring system hind region. MASS A., muscle atrophy scoring system abdominal region.  
a Intraclass correlation coefficient (ICC), calculated for the three raters’ agreement on mean (left and right side) muscle atrophy scores, 
BCS and CNS.  
b Light’s Kappa (κ) calculated for the three raters’ agreement on the table selected (“lean” vs. “adipose”) to evaluate the horses’ left and 
right neck, back, hind and abdominal regions for muscle atrophy using the MASS.   
  












































































Table 3.4 Relationships between neck, back and hind muscle atrophy scores and body composition indicators. 
 Neck scoresa Back scoresa Hind scoresa 
  β P R2m/R2c n β P R2m/R2c n β P R2m/R2c n 
Body condition 
score 
-0.339 <0.001 0.32/0.67 37 -0.377 <0.001 0.35/0.67 32 -0.463 <0.001 0.52/0.77 37 
Cresty neck score -0.190   0.01 0.07/0.67 38         
Neck circ. -0.037 <0.01 0.15/0.69 38         
Stand. neck circ.  -0.750 <0.01 0.16/0.68 38         
Belly girth      -0.029 <0.01 0.19/0.72 33     
Stand. belly girth      -0.527 <0.01 0.19/0.72 33     
Body weight  -0.008 <0.001 0.35/0.68 37 -0.008 <0.001 0.25/0.72 32 -0.009 <0.001 0.29/0.83 37 
Stand. body weight -0.201 <0.001 0.43/0.68 37 -0.198 <0.001 0.32/0.72 32 -0.208 <0.001 0.38/0.83 37 
FFMb,c -0.006   0.13 0.09/0.55 17 -0.003   0.54 0.02/0.67 16 -0.001   0.87 0.00/0.73 17 
Stand. FFMb,c -0.170   0.04 0.15/0.55 17 -0.117   0.29 0.05/0.67 16 -0.058     0.62 0.05/0.67 17 
Body composition indicators relating to the whole body (body condition score, body weight, FFM) were tested for associations 
with atrophy scores of all three regions, and indicators relating to a specific region only (cresty neck score, neck circumference, 
belly girth) were tested for associations with muscle atrophy scores at that region.   
Abbreviations: Circ., circumference. Stand., standardized; refers to the ratio of the body composition indicator to the horses’ 
cannon bone circumference. This ratio is calculated to scale (i.e., standardize) across body size. 
aAtrophy score categories: 1= “no atrophy”, 2= “mild atrophy”, 3= “moderate atrophy”, 4= “severe atrophy”. Left and right-
side mean ratings were used for analysis. 
b Fat-free mass (FFM), was estimated using the formula: FFM= Weight (kg) – [Weight (kg) x (%-body fat)] 93, where %-body 
fat was calculated using the empty-body fat percent (EBFP) formula by Kane et al. 105 , which is based on ultrasonographically 
measured rump fat thickness (RFT): EBFP = 5.47 x RFT + 2.89.    






Figure 3.1 Linear relationships between muscle atrophy scores and body condition scores 
(BCS) or cresty neck scores (CNS) in horses with higher and lower BCS and CNS. 
 
Using the three raters average BCS and CNS scores, horses were categorized as lower BCS 
(≤ 5, A-C: black dots and lines) or higher BCS (> 5, A-C: grey dots and lines), and “no 
visible neck crest” (CNS <2, D: black dots and lines) or “visible crest” (CNS ≥2, D: grey 
dots and lines). Panel plots within plots A-D specify scores assigned by each of three raters 
(A, C and S). Dots were drawn with slight random shift to avoid overplotting. A BCS and 
neck atrophy scores were linearly related in horses with lower (β= -0.64, 95% CI= -0.80, -
0.48, n= 18, R2m/R2c= 0.53/0.67), but not higher BCS (β= 0.12, 95% CI= -0.08, 0.32, n= 
19). B BCS and back atrophy scores were only associated in horses with lower body 
condition (lower BCS group: β= -0.63, 95% CI= -0.82, -0.45, n= 15; higher BCS group: 
β= 0.02, 95% CI= -0.18, 0.22, n= 17, R2m/R2c= 0.51/0.70). C BCS and hind atrophy scores 
were related in horses with lower (β= -0.55, 95% CI= -0.71, -0.40, n= 18, R2m/R2c= 
0.63/0.79), but not higher BCS (β= -0.09, 95% CI= -0.28, 0.10, n= 19). D CNS and neck 
atrophy scores were only related in horses without visible crest (no crest group: β= -0.37, 








Figure 3.2 Linear relationships between horse age and neck, back, and hind muscle 
atrophy scores.  
 
Age displayed in years and dots plotted with slight random shift to avoid overplotting. 
Panel plots in plots A-C illustrate muscle atrophy scores assigned by each rater (A, C and 
S). Age was significantly associated with A neck muscle atrophy scores (β= 0.030, P <0.01, 
n= 38, R2m/R2c= 0.17/0.68), B back muscle atrophy scores (β= 0.037, P< 0.001, n= 33, 
R2m/R2c= 0.24/0.72), and C hind muscle atrophy scores (β= 0.040, P <0.001, n= 38, 





Figure 3.3 Neck, back and hind muscle atrophy scores in horses of varying PPID status.  
Panel plots within graphs A-C represent atrophy ratings by the three evaluators: A, C and 
S. Open boxes show horses not tested for PPID (young horses), light grey boxes show 
PPID-negative horses, medium grey boxes show PPID-equivocal horses and dark grey 
boxes show PPID-positive horses. Box plot shows data median, 25% and 75% quartiles, 
and the mean (black diamond). P-values refer to overall results of Tukey-adjusted pairwise 
group comparisons; analysis was not performed for each rater individually. A Neck atrophy 
scores were significantly higher in PPID-positive (n= 4) vs. negative (n= 23) or vs. untested 
horses (n= 8). B Back muscle atrophy scores were significantly higher in PPID-positive 
(n= 3) compared to PPID-negative (n= 20) or untested horses (n= 7) and were higher in the 
PPID-negative compared to untested horses. C Hind muscle atrophy scores were 
significantly higher in PPID-positive (n= 4) than in PPID-equivocal (n= 3), negative (n= 
23) or untested horses (n= 8).  






 EXPLORING ASSOCIATIONS BETWEEN CIRCULATING INFLAMMATORY 
MARKERS AND MUSCLE MASS IN HORSES 
 Abstract 
In horses, advancing age is associated with loss of skeletal muscle mass and the 
development of a low-grade inflammatory state. A connection between inflammation and 
muscle atrophy has been proposed for elderly humans, however, in horses, data on this 
potential relationship is currently limited. The goal of this study was therefore to determine 
if serum inflammatory markers were associated with muscle mass in horses. In 22 healthy 
horses (2- 31 years of age), muscle atrophy scores (MAS), estimated fat-free mass (FFM), 
and serum creatinine levels were recorded to serve as muscle mass indicators, and serum 
CPR, IL-1RA, IL-6, IL-10, TNFα and IFNγ levels were quantified to serve as inflammatory 
markers. Horses were also classified as affected or unaffected by low-grade inflammation 
based on their inflammatory marker levels. Age was significantly and positively associated 
with IL-10 levels, and while the remaining inflammatory markers were not significantly 
associated with age, trends to a positive association between age and TNFα (P= 0.08) and 
IFNγ (P=0.09) levels were found. Horses affected by low-grade inflammation were 
significantly older than their unaffected counterparts. Age was positively associated with 
MAS and serum creatinine levels, but not with estimated FFM. Inflammatory markers and 
muscle mass indicators were not significantly associated, although trends for a positive 
association between IL-10, IFNγ and MAS of the hind region were observed (P= 0.10 for 
both). When the model was adjusted for age, however, these relationships were no longer 
trending. Horses with low-grade inflammation had significantly higher MAS in the neck 
and hind region than unaffected horses; however, these differences were no longer 




levels of the anti-inflammatory cytokine IL-10 increase with advancing age in healthy 
horses and that sedentary horses experience muscle atrophy as they age. In addition, the 
findings of this study indicate that serum creatinine may be an inappropriate marker of 
muscle mass in old horses as the age-related increase in this marker contradicted the 
observation of higher muscle atrophy scores in older horses. While the results of this work 
suggest that muscle mass and circulating CPR, IL-1RA, IL-6, IL-10, TNFα and IFNγ levels 
are generally unrelated in healthy, sedentary, horses, trends to associations were identified 
which warrant further investigation in a larger study.  
Keywords: horse, inflammation, muscle mass, age 
 Introduction 
The equine immune system undergoes various changes with advancing age 29,55-
57,59,60,125, including an increase in circulating pro-inflammatory cytokine protein and 
mRNA levels 55. The development of a low-grade inflammation has been described in 
elderly people as well 45,126 and is termed inflamm-aging 44. In humans, inflamm-aging has 
been associated with morbidity 46,47 and mortality 51,52. In addition, elevated levels of 
circulating inflammatory mediators (cytokines and acute phase proteins) have been 
associated with a heightened loss of muscle mass and strength in the elderly 49,50, and a role 
of inflammation in the pathogenesis of sarcopenia (a condition characterized by low muscle 
strength and mass or quality 20) in older individuals has been proposed  22,67,69.  
Senior horses appear to be affected by a loss of muscle mass as well 13,29, however, 
little is currently known concerning the relationship between inflammatory mediators and 
muscle mass in horses. A positive correlation between fat-free mass (FFM; a muscle mass 




however, other inflammatory markers tested for correlation with FFM were found not 
significantly associated with this muscle mass indicator 29. In a small pilot-study (n= 12 
horses aged 15-30 years), a significant negative association between circulating TNFα 
mRNA levels and muscle development scores of the thoracic region has been identified; 
however, TNFα expression was not significantly associated with muscle development in 
any other body region (Herbst et al., unpublished results). Because muscle atrophy has 
important implications for horse welfare and athletic performance 88,91 identification of 
modifiable factors involved in the pathogenesis of muscle atrophy is critical.  
Therefore, it was the goal of this study to determine if inflammatory markers (pro-, 
and anti-inflammatory cytokines, and C-reactive protein [CRP, an acute phase protein]) in 
serum were associated with indicators of muscle mass (estimated FFM, muscle atrophy 
scores, and serum creatinine levels). In addition, associations between age and 
inflammatory marker levels, and age and muscle mass indicators were examined. 
 Methods 
4.3.1 Animals  
Twenty-two horses (5 geldings and 17 non-pregnant mares) were selected for this 
study based on their health status (see 2.1.1 Health status). The horses were between 2 and 
31 years old (mean ± SD= 15.41 ± 11.11) and of Thoroughbred (n= 11), Standardbred (n= 
1), Paint (n= 1), Warmblood (n= 1) and mixed breed (n= 8). The horses were kept in groups 
on pasture or semi-drylots at the University of Kentucky Maine Chance Farm or at the C. 




received complementary feeds to preserve body weight. All horses were sedentary (i.e., 
had not engaged in structured exercise) for ≥1 year. 
The animal procedures of this study were approved by the University of Kentucky 
Institutional Animal Care and Use Committee. Some data used in this present study was 
also reported on in a preceding article40 in which both healthy and unhealthy horses were 
included. The present study used only data of healthy horses.  
4.3.1.1 Health status 
A horse was considered healthy if 1) no chronic medical condition(s) were known 
to the farm managers at the time of the study, 2) no signs of acute infection or lameness 
were present on the day of blood collection, 3) the horse had tested negative for pituitary 
pars intermedia dysfunction (PPID) based on a basal plasma adrenocorticotropic hormone 
(ACTH) test performed ~8 months prior the study start date (a detailed description of the 
test and diagnosis can be found in Herbst et al. 40), and 4) the horse’s basal serum insulin 
levels were below the cutoff (≤50 µIU/mL) for insulin dysregulation 127. The blood samples 
for insulin testing were obtained during the study in September and October, and insulin 
was quantified at the Cornell University Animal Health Diagnostic Center (AHDC) using 
a human insulin radioimmunoassay (Millipore, Burlington, MA) validated for use in 
equine serum 128. The horses had not received any medical treatments for at least 1 week 
prior to blood collections.  
4.3.2 Blood collection  
Blood was collected by venipuncture of the jugular vein, once in every horse. For 




in which younger and older animals were mixed. The lag time between the collections in 
groups 1 and 2 was 14 days. The blood samples were centrifuged (800g, 10 min) and the 
serum was frozen at -20°C until further processing. Serum samples underwent maximally 
2 freeze-thaw cycles.  
4.3.3 Muscle mass indicators 
Muscle atrophy scores (MAS) and estimated fat-free mass (FFM) were recorded as 
described in Herbst et al. 40. Briefly, FFM was estimated by measuring rump fat 
ultrasonographically and by using this rump-fat measurement to calculate percent body-fat 
as in Kane et al. 105. Percent body-fat was then used to calculate total body fat weight based 
on the horses’ body weight and body fat mass was subsequently subtracted from body mass 
to arrive at FFM (kg) 30,93. Horses requiring sedation for ultrasonography, or for which no 
clear rump-fat images could be obtained, were excluded from FFM estimation 40 (n= 11 
remained). Three evaluators (A, C, S) assigned MAS to the horses’ neck, back and hind 
regions 40. The scoring scale ranged from 1 (no muscle atrophy; normal muscle mass) to 4 
(severe muscle atrophy), and raters assigned scores to the horses left and right side for 
every scoring region40.  Left and right-side scores were averaged.  
Creatinine was quantified in serum samples to serve as an additional indicator of 
skeletal muscle mass 129. The assay was carried out by the Cornell University AHDC. The 
serum was obtained during the above-described blood collection (4.1.2 Blood collection) 




4.3.4 Inflammatory markers  
A horse C-reactive protein (CRP) sandwich enzyme-linked immunosorbent assay 
(ELISA; Kamiya Biomedical Company, Seattle, WA) was used for serum CRP 
quantification 29. The assay was carried out in accordance with the kit instructions. Serum 
samples were diluted 1:300 29, and absorbance was measured at 450 nm in a microplate 
reader (Bio-Rad Laboratories, Hercules, CA) as recommended in the kit instructions. CRP 
concentrations (ng/mL) were obtained from a calibrator curve (R2= 1) fitted with BioTek 
Gen5 software (Winooski, VT), and were corrected for the dilution factor. Calibrators and 
samples were background adjusted (BioTek Gen5 software). In three samples, 
concentrations were below the detection limit; these samples were assigned concentrations 
of 3.13 ng/mL, which was the lower detection limit of the assay. The mean and range of 
the sample duplicate coefficient of variation (CV) was 3.14%, and 0.0%-7.18%, 
respectively.  
An equine-specific interleukin-1 receptor antagonist (IL-1RA) sandwich ELISA (R 
& D Systems, Minneapolis, MN) was used to quantify serum levels of the anti-
inflammatory cytokine IL-1RA 130. The assay was performed in accordance with the kit 
manual. Neat serum samples were used, and absorbance was measured at 450nm 
(microplate reader; Bio-Rad Laboratories) with wavelength correction set to 540 nm, as 
recommended in the assay instructions. Samples and calibrators were background-
corrected, and a calibrator curve was fitted with the BioTek Gen5 software. IL-1RA 
concentrations (ng/mL) were obtained from the calibrator curve (R2= 1). The IL-1RA 
concentration was below the detection limit in one sample which was assigned a 




CV of >20% and two samples were not assigned a CV because one of the sample pairs had 
a value below the lower detection limit; these samples (n= 8/22) were excluded from 
analysis. The CV mean and range of all remaining duplicate samples was 9.0% and 0.0-
16.7%, respectively.  
Serum concentrations of the pro-inflammatory cytokines IL-6, TNFα and IFN-γ 
and of the anti-inflammatory cytokine IL-10 were assessed using an equine cytokine 
magnetic bead assay (Millipore Sigma, St. Louis, MO) 128 . The serum samples were first 
centrifuged (17,000g, 10 min) to remove particulates and the assay was then performed per 
kit instructions on neat serum, except for suspending the beads in wash buffer instead of 
sheath fluid for acquisition by the Luminex® 200™ instrument (Luminex Corp., Austin, 
TX). Cytokine concentrations (pg/mL) were obtained from standard curves (R2= 1) created 
with the xPONENT® software (Luminex Corp.). Concentrations were below the detection 
limit for up to 55% of the samples, depending on the cytokine (samples below the limit: 
n= 10, n= 12, n= 6 and n= 6, for IL-6, IFNγ, IL-10 and TNFα, respectively). These samples 
were assigned the value of the lower detection limit: IL-6 (3.49 pg/mL), IFNγ (n= 412.16 
pg/mL), IL-10 (39.40 pg/mL) and TNFα (4.31 pg/mL).  
Horses in which the serum levels of at least one of the inflammatory markers was 
>2-fold above the 75th-percentile of the marker in the young/adult group were considered 
affected by low-grade inflammation. This definition was based on the observation that in 
humans, aging is associated with a 2-4-fold elevation in serum inflammatory mediators, 
which is an increase much below what is seen during acute infection and therefore 
considered low-grade 45. Supplemental table 4.1 details the number of inflammatory 




4.3.5 Statistical data analysis 
Data was analyzed, and figures were created, using R (version 4.0.4 82). To 
determine associations between atrophy scores and horse age, linear mixed effects models 
115 were fitted with horse and rater included as random effects and age as the fixed effect. 
Associations between age and estimated FFM and serum creatinine were assessed using 
linear fixed effects regression models with age fitted as the explanatory variable. 
Differences in muscle mass indicators between young/adult and old horses were 
determined using an unpaired T-test for estimated FFM and creatinine, and linear mixed 
effects models 115 for muscle atrophy scores (age group fixed effect, horse and rater random 
effects). Relationships between age and inflammatory makers were explored using linear 
fixed effects models with age fitted as the explanatory variable. Differences in 
inflammatory markers between young/adult and old horses were studied using an unpaired 
T-test. 
Relationships between inflammatory markers and muscle mass indicators were 
assessed using linear mixed effects models 115 for muscle atrophy scores (inflammatory 
marker fixed effect, horse and rater random effects), and linear fixed effects models for 
estimated FFM and creatinine (inflammatory markers fixed effects). For muscle mass 
indicators that were significantly associated with age, a second set of models was run with 
age included as a covariate. Differences in muscle mass indicators between horses with vs. 
without low-grade inflammation were determined using unpaired T-tests (estimated FFM 
and creatine) and linear mixed effects models (muscle atrophy scores) with random effects 
as described above and inflammation group as the fixed effect. For those muscle mass 




For fixed effects models, conditional and marginal coefficients of determination 
were calculated (r2c , r2m , respectively), using the Nakagawas’s r2 function 114, to indicate 
the degree of variance explained by the random and fixed effects, and the fixed effects, 
respectively 113. For linear fixed effects models, traditional coefficient of determination (r2) 
were calculated.  
All model data was visually inspected for acceptable homoscedasticity and normal 
distribution of residuals using diagnostic plots. If deviations occurred, the response variable 
was natural logarithm (ln) transformed. For the IFNγ and age regression model, the 
response variable was double ln transformed to achieve acceptable normal distribution of 
residuals. Figures corresponding to regressions conducted on ln-transformed data are 
plotted on a ln-y-axis. 
For the IL-1RA, one extreme outlier, which was 6.92-fold above the remaining data 
points, was identified and placed at the 95th-percentile of the IL-1RA data. No further 
extreme outliers were present in the remaining data of this study. Because some data points 
for a few parameters (e.g., MAS and FFM) were missing, the sample size is indicated 
throughout the results section.  
 Results  
4.4.1 Horse demographics 
Based on the three-raters average muscle atrophy scores, some degree of muscle atrophy 
(MAS ≥2) was present in the neck region of 50% (n= 11/22) of the horses, in the back 
region of 35% (n= 7/20) of the horses, and in the hind region of 59% (n= 13/22) of the 




12) while the other half was old (≥ 20 years of age, n= 10). Of all horses, 36% (n= 8/22) 
were affected by low-grade inflammation. The majority (75%; n= 6/8) of these horses were 
≥20 years of age.  
4.4.2 Associations between muscle mass and age  
Age was significantly and positively associated with neck (P= 0.015), back (P 
<0.001), and hind (P= 0.001) muscle atrophy scores, as well as with serum creatinine levels 
(P= 0.005) (Figure 4.1 A-C and E, respectively). Age was not associated with estimated 
FFM (P >0.05; Figure 4.1 D).  
Old horses (≥ 20 years of age) had significantly higher neck, back, and hind muscle 
atrophy scores than young/adult horses (P= 0.05, P= 0.01, P= 0.02, respectively). The 
estimated mean differences between the age groups was 0.41 scoring points (95%-CI= -
0.002, 0.82) for the neck region, 0.57 points (95%-CI= 0.15, 1.00) for the back region, and 
0.62 points (95%-CI= 0.12, 1.12) for the hind region. There was no difference between the 
age groups in estimated FFM (P= 0.42), however serum creatinine levels were significantly 
higher in the old group (estimated mean group difference [EMD]= 0.27; 95%-CI= 0.12, 
0.41; P= 0.001). 
4.4.3 Associations between inflammatory markers and age  
Age was not significantly associated with serum CRP, IL-1RA, IL-6, TNFα or IFNγ 
levels (P >0.05; Figure 4.2 A-C and E-F, respectively), however, serum IL-10 levels and 
age were linearly related (P= 0.020; Figure 4.2 D; β= 0.05; 95%CI= 0.01, 0.10; Figure 4.2 
D). While not significant, trends for positive associations between TNFα and age (P= 0.08; 




IL-10 levels were also significantly higher in the old compared to the young/adult 
group (EMD= 2.75-fold; 95%-CI= 1.05, 7.24; P= 0.04; Table 4.1). The age groups did not 
differ significantly in serum levels of CRP, IL-1RA, IL-6, INFγ, or TNFα levels (P >0.05), 
although a trend to higher TNFα levels in old horses compared to the young/adult group 
was found (P= 0.08) (Table 4.1).  
Horses affected by low-grade inflammation were significantly older than 
unaffected horses (EMD= 10.6 years; 95%CI= 1.25, 19.9; P= 0.03). The estimated mean 
age of horses affected by low-grade inflammation was 22.10 years (95%-CI= 14.71, 29.50), 
and the estimated mean age of unaffected horses was 11.6 years (95%-CI= 5.96, 17.20).  
4.4.4 Associations between muscle mass and inflammatory markers 
None of the inflammatory markers were significantly associated with estimated 
FFM, serum creatinine levels, or MAS of the neck, back or hind region (P >0.05), although 
a trend for positive associations between serum IL-10 levels and hind region atrophy scores 
(P= 0.10), and IFNγ levels and hind region atrophy scores (P= 0.10) was observed (Table 
4.2).  
Because age was related to MAS and creatinine levels (see 3.2 Associations 
between muscle mass and age) a second set of models was run with age included as a 
covariate. Similar to the univariable models, relationships between the inflammatory 
markers and creatinine or MAS of the neck, back or hind region  were not significant (Table 
4.2). Trends for associations were not observed in the age-adjusted models (Table 4.2).   
Horses affected low-grade inflammation were estimated to have on average 0.54 




P= 0.009); however, when the model was adjusted for age, this difference was no longer 
significant, but still trending (P= 0.07). There was no significant difference in back atrophy 
scores between horses affect vs. unaffected by low-grade inflammation in the univariable 
or in the age-adjusted model (P= 0.07; P= 0.49, respectively). Hind region muscle atrophy 
scores were estimated to be on average 0.57-points higher in horses affected by low-grade 
inflammation vs. the unaffected horses in the univariable model (95%CI= 0.03, 1.10; P= 
0.04); although this difference was no longer significant once the model was adjusted for 
age (P= 0.38). There was no difference in FFM or serum creatinine levels between the 
inflammation groups (P= 0.80; P=0.24, respectively). As age was not associated with FFM 
(Figure 4.1 D), an age-adjusted model was not calculated for this parameter. The age-
adjusted creatinine model showed no difference between the inflammation groups (P= 
0.95).  
 Discussion  
This  study had three main finings 1) advancing age was significantly associated with 
higher MAS and serum creatinine levels, while unrelated to estimated FFM,  2) age was 
significantly associated with increasing serum IL-10 levels, and trends for a positive 
association between age and TNFα and IFNγ levels were observed, and 3) while muscle 
mass indicators were not significantly associated with the inflammatory markers, trends to 
positive associations between IL-10, INFγ and hind region muscle atrophy scores were 
found.  
To the authors’ knowledge, this study is the first to suggest a relationship between 




in humans and mice, where age-related increases in circulating IL-10 and IL-10 production 
by leukocytes have been described 131,132. In contrast to the findings of this present study, 
Zak et al. 133 reported no significant difference in serum IL-10 levels between adult (≤16 
years of age) and old (≥18 years of age) horses. These divergent results could have resulted 
from differences in the age distribution of the horses in each age group, as well as 
differences in sample size (n= 6 adult and n= 6 old in Zak et al. 133, vs 12 young/adult and 
n= 10 old in this present study), as the sample size of the previous study could have been 
too small to detect significant differences. 
While an age-related increase in IL-10 seemingly contradicts the concept of aging as 
a low-grade pro-inflammatory state 44, a model has been proposed in which the age-related 
elevation in pro-inflammatory cytokines can be balanced through concomitant increases in 
anti-inflammatory cytokines to promote successful aging 134,135. Horses that participated in 
this present study were considered healthy, and trends to increased serum TNFα and IFNγ 
levels with advancing were found concomitant with significant increases in IL-10. In 
previous studies in healthy horses, age-related increases in the proportion of immune cells 
that respond with IFNγ and TNFα production to in vitro stimulation have been shown 55,56 
as well, along with increases in circulating TNFα levels 55, supporting the findings of trends 
to elevated levels of circulating TNFα and IFNγ found in this present study. These findings 
may therefore indicate that the model of a balanced increase in pro- and anti- inflammatory 
status during successful aging may also apply to horses.   
A novel approach to identifying horses with low-grade inflammation (inflamm-
aging) was explored in this study. In people, 2-4 fold increases in circulating cytokines or 




inflammatory marker development over time in individual horses, those with at least one 
inflammatory maker >2-fold above the 75th-percentile of the young/adult group were 
considered affected. Using this definition, eight horses were found to be affected by low-
grade inflammation, the majority of which (n= 6) were ≥20 years old. In addition, higher 
neck and hind region MAS were found in low-grade inflammation affected horses, 
suggesting that this definition might be valid and useful. Further study of cytokine 
development in individual horses over time, and a larger scale investigation of associations 
between diseases and this inflamm-aging definition, or a modified version thereof, is 
however, warranted to establish a definition with clinical relevance and scientific merit. In 
addition, the results of this present study relating to the inflamm-aging definition applied, 
should be interpreted with caution, as this study was not specifically designed to establish 
an inflamm-aging definition, and the sample size was small. Furthermore, only a limited 
number of cytokines was investigated in this work.  
Age was positively associated with neck, back and hind muscle atrophy scores in this 
group of healthy horses, which corroborates results of previous studies reporting a loss of 
muscle mass in senior horses 13,27,40. In stark contrast to this finding, serum creatinine levels 
were shown to increase with advancing age in this study, suggesting that older horses had 
greater muscle mass than younger horses. Creatinine is produced during the breakdown of 
creatine phosphate in skeletal muscle and circulating levels are considered representative 
of total muscle mass 129. Thus, in humans, creatinine in blood or urine is used as a muscle 
mass indicator 17,136, and lower creatinine levels were found in sarcopenia-affected 
individuals compared to unaffected counterparts of similar age 137. Nevertheless, age-




suggesting that while serum creatinine might be a good indicator of muscle mass in studies 
with age-matched controls, age-related increases may be observed independent of changes 
in muscle mass, rendering serum creatinine a biased marker of muscle mass in older 
individuals.  
While studies in humans found associations between circulating inflammatory 
markers and loss of muscle mass and strength 49,50, this present study did not find 
significant associations between inflammatory makers and MAS or estimated FFM. The 
findings of this present study are also in contrast to results of a previous study in older 
horses, in which a positive association between serum IL-6 levels and estimated FFM was 
reported 29. These divergent findings might be in part explained by the considerably small 
number of horses for which FFM data was available in this present study (n= 11),  the 
difference in age-range of the horses enrolled in this, compared to the previous study (18-
29 years 29 vs. 2-31 years in this present work), and difference in assays used to quantify 
IL-6 (Luminex [present study] vs. ELISA 29) . In addition, it should be considered that the 
FFM estimation method applied in this study might have limited accuracy 29, as discussed 
in more detail in Herbst et al., 40. Future studies using methods with higher accuracy, such 
as D2O dilution 37, may permit detection of relationships between FFM and inflammatory 
markers in horses.  
While linear associations between MAS and inflammatory markers were not 
significant in this study, trends for positive associations between INFγ, IL-10 and hind 
muscle atrophy scores were found, as well as significantly higher neck and hind muscle 
atrophy scores in horses affected by inflamm-aging in the age-unadjusted model. These 




inflammatory markers in larger studies. The results of this present work indicate however, 
that any contribution of circulating inflammatory mediators to the development of muscle 
atrophy may be small, given that the amount of variance in muscle mass indicators 
explained by the inflammatory markers was relatively low in the regression model, and 
adding age as a covariate negated significant differences in MAS seen in horses with low-
grade inflammation compared to their unaffected counterparts.  
Aside from the small sample size of this study, further limitations were present. While 
inter-rater reliability of the muscle atrophy scoring system used in this study was found 
acceptable for ratings of the neck, back and hind region, the system has not yet been 
formally validated for accurate representation of muscle mass or correct anchoring of the 
scoring scale (i.e., validation that a score of 1 truly represents no atrophy or normal muscle 
mass) 40. In addition, a link between obesity and inflammation has been shown in humans 
139, and obesity appears to be related to inflammatory status in horses as well 56. The effect 
of adiposity on the relationship between age and inflammatory markers was not accounted 
for in this study, and it is further possible that adjusting models for adiposity could reveal 
correlations between inflammatory markers and muscle mass indicators that were not 
found in this present study.  
 Conclusion 
In horses, serum IL-10 levels and muscle atrophy appear to increase with advancing 
age. Serum creatinine levels might be a biased marker of muscle mass in older horses, and 




indicators were found in this study, trends were observed which warrant further 





Table 4.1 Circulating inflammatory markers in old compared to young/adult horses.  
Levels of circulating inflammatory makers were compared between the age groups 
(young/adult= <20 years of age; old ≥ 20 years of age) using an unpaired T-test. P-values 




Mean ± S.D. 
Old 
Mean ± S.D. 
P-value 
CRP 11889.72 ± 7205.74 12936.70 ± 11784.41 0.80 
IL-1RA 0.58 ± 0.21 0.68 ± 0.89 0.60a 
IL-6 25.25 ± 36.52 78.14 ± 115.35 0.15 
IL-10  181.19 ± 212.79 444.73 ± 456.32  0.04*a 
IFNγ 872.30 ± 1352.25 1321.10 ± 1282.75 0.20a 
TNFα 17.49 ± 20.35 69.05 ± 85.44  0.08†a 
* Significant difference between the age-groups at P≤0.05. 
† Trend to differences between the age-groups at P= 0.06 – 0.10. 









Table 4.2 Associations between muscle mass indicators and inflammatory markers.  
Regression coefficients (β), P-values, and coefficients of determination (r2c and r2m for mixed models, and r2 for simple linear models) 
are shown. Two sets of models were run. Set one contained only the explanatory variable and no covariate (COV= “None”) and set two 
contained ages as a covariate (COV= “Age”). Covariate models were not run for estimated FFM, as age was not associated with this 
parameter (Figure 4.1 D). Two decimals are shown for P-values, at least two decimals are shown for r2, and at least 3 decimals are 
shown for slopes, so that a minimum of one none zero decimal is shown for all data, unless the true value was zero.  
Marker COV MAS Neck MAS Back MAS Hind Estimated FFM Creatinine 
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e-04 
0.50 0.28c 
Abbreviations: COV; Covariate. Indicates whether age was included as a covariate in the regression.  
a Only horse included as a random effect in these models as inclusion of rater resulted in singular fit.  
b Slope of model with ln-transformed response variable.  
c Adjusted r2 for linear fixed effects model with age included as a covariate.  






Figure 4.1 Associations between horse age and muscle mass indicators.  
Three raters (A, C and S) evaluated the horses for muscle atrophy in the neck (A), back 
(B), and hind (C) regions (scoring scale: 1 [no atrophy] – 4 [severe atrophy]40). Averages 
of scores assigned to the horses’ left and the right side were used for analysis and are 
plotted. Dots were plotted with a slight jitter to avoid overplotting. P-values, slopes (β), 
and conditional (r2c), marginal (r2m) and regular (r2) coefficients of determination are 
shown. A) Neck muscle atrophy scores (MAS) and age were significantly related (n= 22). 
B) Back muscle atrophy scores (MAS) were significantly associated with age (n= 20). C) 
Hind muscle atrophy scores (MAS) were significantly related to age (n= 22). D) Estimated 
fat-free mass (FFM) was not significantly associated with age (n= 11). E) Serum creatinine 






Figure 4.2 Associations between horse age and inflammatory markers. 
P-values, slopes (β), and coefficients of determination (r2) are shown. Dots were plotted 
with a slight jitter to avoid overplotting. A) CRP levels were not significantly associated 
with age (n= 22). B) IL-RA levels were not significantly associated with age (n= 14). C) 
IL-6 levels were not significantly associated with age (n= 22). D) IL-10 levels were 
significantly associated with age (n= 22). E) IFNγ was not significantly associated with 






 MONOCYTE FUNCTION IN SENIOR HORSES  
 Abstract  
Studies investigating age-related changes in the function of monocytes are currently 
limited for horses.  Thus, the goal of this study was to determine the effect of aging on 
monocyte phagocytosis capacity and pro-inflammatory cytokine responses to bacterial  
lipopolysaccharide (LPS). Seven healthy young (4-6 years of age) and seven healthy old 
(>20 years of age) horses were enrolled in the study. Phagocytosis of E. coli and pro-
inflammatory cytokine (TNFα) responses to LPS were measured by flow cytometry. Gene 
expression of pro-inflammatory cytokines (TNFα, IL-1β, IL-6, IL-8, IL-18, CCL-5, CCL-
2) in response to LPS was measured in peripheral blood mononuclear cells (PBMCs) by 
RT-qPCR. In addition, pro-inflammatory cytokine gene expression in response to LPS was 
measured in whole blood samples. PBMCs and whole blood samples were incubated for 
2h and 6h with a low (0.01µg/mL) or a high (1µg/mL) dose of LPS. Body condition scores 
(BCS) were recorded in all horses and two sets of statistical models were applied to 
compare the age groups, one adjusted for BCS and one unadjusted. The percentage of 
monocytes that phagocytosed E. coli after 2h of incubation was significantly lower in 
monocytes from old compared to young adult horses in the BCS-adjusted model. 
Significantly higher IL-1β expression was found in PBMCs stimulated with 0.01µg/mL 
LPS for 2h in the old compared to the young adult group (BCS-adjusted and unadjusted 
models). In LPS-stimulated whole blood samples from old horses a significantly lower IL-
8 and IL-6 expression was found after 6h of incubation with 0.01µg/mL LPS and after 2h 
of incubation with 1µg/mL LPS, respectively (BCS-adjusted models). The results of this 




LPS may be altered in old horses. In addition, the whole blood IL-8 and IL-6 gene 
expression responses to LPS appear to be diminished in old horses. These findings could 
have implications for senior horse health which warrants further investigation. While study 
of the effect of BCS on monocyte functions and whole blood LPS responses was not a main 
goal of this work, it appears that BCS may alter innate immune cell function, as significant 
differences between the age groups were often not apparent until the models were adjusted 
for BCS. 
Key words: horse, aging, monocyte, inflammation, phagocytosis, innate immunity  
 
 Introduction  
Aging is accompanied by changes in the immune system 43, commonly referred to as 
immunosenescence. Hallmarks of immunosenescence in people include reduced naïve 
immune cell counts in peripheral blood, relative increases in memory cells, and low-grade 
inflammation 43, termed inflamm-aging 44. Indicators of immunosenescence have been 
associated with decreased immune responses to vaccination 140, multi-morbidity 141 and 
mortality 142 in the elderly.  
The equine immune system undergoes immunosenescence as well. For example, 
multiple studies have described signs of inflamm-aging 29,55-57,143,144, reduced lymphocyte 
proliferation 145,146, as well as a reduced anamnestic response to vaccination 146 in old 
horses, and old horses also appear to remain susceptible to influenza infection despite 




While both the adaptive and the innate arm of the immune system are affected by 
immunosenescence, the effects of aging on the innate immune system are less understood 
58. Current data suggest that aging alters the function of various innate immune cells 148, 
and in particular of monocytes 58,62,149,150. Monocytes perform crucial functions in the 
immune response to pathogens such as serving as macrophage and dendritic cell reservoirs, 
antigen presenting cells, phagocytes and pathogen sensors 149. Pathogens are sensed 
through pattern recognition receptors (PRRs), such as Toll-like-receptor (TLR)-4. TLR-4 
recognizes the Gram-negative bacteria membrane component lipopolysaccharide (LPS), 
which is first delivered to cell surface receptor CD-14 by LPS-binding protein, and then 
transferred from CD-14 to TLR-4 and its accessory protein MD-2 151-153. Downstream of 
TLR-4-mediated LPS recognition, various pro-inflammatory cytokines are induced 151,152 
which coordinate subsequent immune responses.  
Hearps, et al. 62 found that monocytes from older people (66-72 years) responded 
with an increased pro-inflammatory cytokine (TNFα) production to LPS activation when 
compared to monocytes from younger adults (21-45 years). In addition, a reduction in 
monocyte and macrophage phagocytosis capacity has been described in the elderly 62,150,154, 
and reduced efferocytosis (clearance of apoptotic cells) by monocytes and macrophages 
has been proposed as a factor contributing to inflamm-aging 149,154.  
In horses, information on age-related changes in monocyte function is currently 
sparse. To the authors knowledge, only three studies have investigated monocyte function 
in old horses, and all studies examined pro-inflammatory responses. McFarlane and 
Holbrook 57 found an age-related increase in TNFα protein production in PBMCs 




related increases in gene expression of various pro-inflammatory cytokines in LPS-
stimulated PBMCs. Adams, et al. 56 were the only group to measure the pro-inflammatory 
response in monocytes directly and showed an increased proportion of TNFα-producing 
monocytes post in vitro stimulation with PMA/ionomycin in old compared to young horses. 
While these findings provide valuable first insights into monocyte function in the old horse, 
it is currently unclear if aging affects the phagocytic function of monocytes in horses, as 
well as their pro-inflammatory responses to varying doses of LPS and over time.   
Therefore, it was the goal of this study to assess if aging alters the phagocytosis 
capacity of monocytes in horses, as well as the pro-inflammatory cytokine responses to 
two doses of LPS (0.01 µg/mL and 1 µg/mL) and after incubation for 2h and 6h. In 
addition, the effect of aging on the whole-blood pro-inflammatory cytokine responses to 
LPS was examined, and the LPS-induced TLR-4 and CD-14 gene expression responses 
were studied in PBMCs and in whole blood.   
 Methods 
5.3.1 Study design 
Peripheral blood samples were collected from young adult (4-6 years) and old horses 
(21-26 years). Collections occurred between 0750h and 1040h on three separate days 
(Figure 5.1). Blood samples were used for analysis of monocyte phagocytosis-capacity 
(collection 1), cytokine and receptor responses to LPS in whole blood (collection 2), and 
in PBMCs (collection 3) (Figure 5.1). On collection days, all horses were examined for 
overall health (see 5.3.2.2 Health status). In addition, horses were tested for two common 




(ID) (Figure 5.1; for testing details see 5.3.2.2 Health status) and body composition data 
was recorded (see 5.3.2.1 Body Composition; Figure 5.1). 
5.3.2 Animals  
Seven female old (mean age ± SD= 23.00 ± 2.16 years) and seven female young-
adult horses (5.14 ± 0.90 years) participated in the study. All old horses were 
Thoroughbreds, young adult horses were Thoroughbreds (n= 5) or of mixed breed (n= 2). 
The horses were housed at the University of Kentucky Department of Veterinary Science  
(UK VS) Oran Little Farm in Versailles, KY or at the UK VS North Farm in Lexington, 
KY. The horses’ diet, besides pasture grazing, was tailored to their individual needs and 
blood was collected from overnight grain fasted animals. None of the horses had performed 
structured exercise for at least 11 months prior to the study. All horses were kept in cohorts 
on pasture or semi-drylots. Five of the young adult horses were separated through a fence 
from their larger herd ≥3 days prior to blood collections, with no changes in diet, to permit 
safe handling during blood draws. All animal procedures were approved by the UK 
Institutional Animal Care and Use Committee (IACUC). 
5.3.2.1 Body composition 
Horses were rated for body condition (BCS; 1[extremely emaciated] – 9[extremely 
fat] 98) and muscle atrophy (MAS; 1[no atrophy] – 4[severe atrophy] 40) by an experienced 
evaluator at two timepoints during the study (Figure 5.1). Half scores were permitted for 
MAS and quarter scores for BCS. Results and a comparison between the age groups are 





5.3.2.2  Health status 
All old horses were screened once in October for PPID (Figure 5.1) using basal 
plasma adrenocorticotropic hormone (ACTH) quantification. ACTH was measured in 
ethylenediaminetetraacetic acid (EDTA)-plasma with a chemiluminescent immunometric 
assay (Immulite® 1000 ACTH; Siemens, Munich, Germany) validated for equine samples 
103. The assay was carried out by the Animal Health Diagnostic Center (AHDC) at Cornell 
University. Based on diagnostic basal ACTH levels for fall-months 102, no horse was PPID-
positive. The ACTH mean ± SD was 47.13 ± 27.50.  
All horses were tested twice during the study for insulin dysregulation (ID; Figure 
5.1) using basal serum insulin quantification which was carried out with a human insulin 
radioimmunoassay (Millipore, Burlington, MA), validated for use in horses 155. The assay 
was carried out by the AHDC at Cornell. Based on diagnostic basal insulin levels 127, no 
horse was insulin dysregulated on either screening day (Figure 5.1). The insulin means ± 
SDs on screening day one were: 14.13 ± 6.27 (young adult horses) and 15.22 ± 2.80 (old 
horses). The insulin means ± SDs on screening day two were: 16.44 ± 10.45 (young adult 
horses) and 15.75 ± 5.96 (old horses).  
On sample collection days (Figure 5.1), a clinical exam was performed (Supplemental 
file 1) for signs of acute or chronic disease/disorder or trauma. Based on these exams, 11 
horses (n= 5 old; n= 6 young-adult) were considered healthy on collection day 1, 13 horses 
(n= 6 old; n= 7 young-adult) on day 2, and all 14 horses on day 3. Horses identified as not 
healthy on collection days 1 and 2 presented with signs of diarrhea (collection day 1 and 
2, n= 1) or a slight lameness (collection day 1, n= 2), which had resolved on collection day 




recovered and were health based on the exam. Only data from healthy horses was used for 
data analysis. The horses had not received any medical treatments for at least 6 days prior 
to blood collections. 
5.3.3 Monocyte phagocytosis assay 
Peripheral blood was collected into heparinized tubes (sodium heparin) and 
mononuclear cells (PBMCs) were isolated using Ficoll gradient centrifugation (1.077 g/mL 
Ficoll-Paque Plus™, Cytiva, Malborough, MA), as previously described 55. PBMCs were 
washed three times in Dulbecco’s Phosphate Buffered Saline (DPBS, without Ca/Mg, 
Cytiva) and cell viability and cell count were determined using a Vi-CELL™ Counter-XR 
(Beckman Coulter, Brea, CA). Viability exceeded 90% for all samples. PBMCs were 
suspended in complete media (cRPMI: 1640 RPMI [w/o L-glutamine; Cytiva] with 2.5% 
fetal equine serum [FES, Biowest, Nuaille, France], 1% L-glutamine-Penicillin-
Streptomycin solution [L-glutamine 200mM,  Penicillin 10000U, Streptomycin 10mg; 
Sigma-Aldrich, St. Louis, MO], and 0.1% 2-mercaptoethanol [GibcoTM, Grand Island, NY; 
55mM], as in [Adams et al., 2008]) and plated at a density of 4x106 PBMCs/mL/well in 
24-well plates (8 wells/horse). Four wells/horse were treated with inactivated Alexa Fluor® 
488-conjugated E. coli (0.0625µL/well; K12 strain, BioParticles®, InvitrogenTM, 
Waltham, MA), reconstituted in 100 µL NaN3(2 mM)-DPBS (NaN3 from Sigma-Aldrich) 
per the manufacturer’s instructions. The remaining four wells/horse were left untreated to 
serve as negative controls. Half of the treated and untreated samples were incubated at 37℃ 
and 5% CO2. The remaining samples were incubated on ice with ambient CO2 to serve as 
controls for extracellular E. coli adhesion, as monocyte phagocytosis is inhibited at low 




were transferred to 96-well plates, centrifuged for 10 min at 500g and 4℃ and the 
supernatant was discarded. Pelleted PBMCs were washed once with chilled DPBS 
(centrifugation settings as above) and were then re-suspended in chilled 1mM EDTA-
DPBS (EDTA from Millipore) for analysis on an AttuneTM NxT Flow Cytometer (Thermo 
Fisher Scientific, Waltham, MA). The gating strategy and calculation of monocyte 
phagocytosis capacity are illustrated and explained in Figure 5.2.  
5.3.4 Monocyte cytokine and receptor responses to LPS 
PBMCs were isolated and viability and cell count were determined as described 
above (5.3.3. Monocyte phagocytosis assay). Viability was >90% for all samples. PBMCs 
were plated at a density of 4x106 PBMCs/mL/well (6 wells/horse) in 24-well plates. 
Brefeldin A (10µg/mL; Sigma-Aldrich) was added to all wells to induce intracellular 
accumulation of protein as required for intracellular staining 55. PBMCs were incubated 
with a low dose of LPS (L-LPS; 0.01µg/mL; 0111:B4 E. coli; Sigma-Aldrich), a high dose 
of LPS (H-LPS; 1µg/mL), or without LPS (negative control) for 2h and 6h at 37°C and 5% 
CO2. After incubation, PBMC viability was re-tested in samples from a subset of randomly 
selected animals (n= 3 old and n= 3 young adult horses). The viability exceeded 90% for 
all sample types (i.e., negative control, L-LPS and H-LPS treated), both after 2h and 6h of 
incubation. 
5.3.4.1 Monocyte TNFα intracellular staining 
Post incubation, aliquots (200 µL) of all samples were transferred to a 96-well plate, 
the PBMCs were 2%-paraformaldehyde fixed (Sigma-Aldrich; 100µL/well) and the plate 




described 55. Briefly, the PBMCs were washed once with saponin buffer (saponin from 
Sigma-Aldrich; 0.1% saponin, 1% NaN3, 1% FBS in DPBS) and incubated on ice for 30 
min with a monoclonal mouse anti-equine TNFα antibody (100 µL of 1:10 dilution in 
saponin buffer; antibody [HL801] provided by Dr. Robert McKay, University of Florida, 
157). The stained PBMCs were washed once with saponin buffer and were incubated on ice 
for 30 min with a FITC-conjugated secondary antibody (F(ab’)2 goat anti-mouse IgG (H + 
L); Invitrogen; 100 uL of 1:1000 dilution in saponin buffer), washed again once in saponin 
buffer and re-suspended in DPBS for acquisition by the flow cytometer (AttuneTM NxT 
Flow Cytometer; Thermo Fisher Scientific). Monocyte populations were selected based on 
forward and sideward scatter profiles (Supplemental figure 5.2), as above 56. The %-TNFα+ 
monocytes in LPS stimulated samples was identified by setting a gate on 1% (± 0.1) 
positive singlet monocytes in negative control samples and recording the corresponding 
%-TNFα+ singlet monocytes in the LPS stimulated samples (Supplemental figure 5.2). 
Percentages recorded in the negative control samples were subtracted from those recorded 
in the LPS-stimulated samples. Median fluorescence intensity (MFI) was recorded at the 
above-described gate settings as well, and MFIs recorded in the negative control samples 
were subtracted from those obtained in LPS-stimulated samples.  
5.3.4.2 Monocyte cytokine and receptor gene expression  
Post PBMC incubation with LPS, aliquots (500 µL) were transferred to 
microcentrifuge tubes, the PBMCs were pelleted by centrifugation, re-suspended in 1 mL 
TRIzol™ (Invitrogen) and frozen at -80°C until further processing 29. The RNA was isolated 
using chloroform-phenol extraction 29. Briefly, chloroform (200 µL; Thermo Fisher 




15min), and the aqueous phase was obtained. The RNA was precipitated in isopropanol 
(320 µL; Thermo Fisher Scientific) and washed in 75% ethanol (800 µL; Sigma-Aldrich). 
The pellet was solubilized in 60 µL RNAse-free H2O by incubation at 60°C for 10 min. 
The samples were stored at -80°C until further processing. The RNA was quantified using 
an Epoch microplate spectrophotometer (BioTek, Winooski, VT) and 1 µg RNA was 
reverse transcribed into complementary DNA (cDNA) as in Siard-Altman, et al. 29. The 
cDNA was stored at -20°C. For qPCR, TaqMan primers and probes (Thermo Fisher 
Scientific; exon-spanning probes unless indicated otherwise) for CD-14 
(Ec04260516_gH), TLR-4 (Ec03468994_m1), TNFα (Ec03467871_m1), IL-1β 
(Ec04260298_s1; primers and probe within single exon), IL-6 (Ec03468678_m1), IL-8 
(Ec03468860_m1), IL-18 (Ec03468749_m1), CCL-5 (Ec03468106_m1), CCL-2 
(Ec03468496_m1) and β-gus (Ec03470630_m1; used as a reference gene 29) were each 
combined (1:11) with rox-dye containing master mix (Seni-FastTM Probe Lo-Rox; Bioline, 
London, UK) 29. A pipetting robot (epMotion® 5070; Eppendorf, Hamburg, Germany) was 
used to combine 4.5 µl cDNA and 5.5 µl mastermix-primer/probe mixture in 384-well 
plates 29. A QuantStudioTM 7 Flex Real-Time PCR system (Thermo Fisher Scientific) was 
used for qPCR, set to 2 min at 50°C, 10 min of 95°C followed by 40 cycles of 15s at 95°C 
and 60s at 60°C 29. While gene expressions were measured in PBMCs, inflammatory and 
receptor responses were expected to mainly originate from TLR-4 bearing monocytes 126.  
Raw fluorescence data obtained from the RT-qPCR experiment was imported to 
LinRegPCR version 2020 158,159 for baseline correction, estimation of PCR efficiency per 
primer/probe set, and calculation of efficiency corrected starting concentrations (N0) 158. 




were calculated as FD= (N0 of gene of interest) / (N0 of β-gus in the same sample), and 
ΔFD were calculated as: (FD of LPS stimulated sample) – (FD of unstimulated control) to 
correct for LPS-unspecific responses. Samples were excluded from analysis if N0 was not 
assigned by LinRegPCR due to failed quality control. Duplicate averages were used for 
ΔFD calculations unless a sample of the pair was excluded due to low quality, then the 
remaining sample was used for ΔFD calculation. Efficiencies ranged from 64-84% and are 
listed in supplemental table 5.3. 
 
5.3.5 Whole blood cytokine and receptor responses to LPS 
Peripheral blood was collected into lithium-heparin tubes and incubated with L-LPS 
(0.01 µg/mL), H-LPS (1 µg/mL), or without LPS (negative control) for 2h and 6h at 37°C 
and 5% CO2. For the desired concentrations, LPS was diluted in DPBS; the negative 
control was incubated with DPBS alone. Post incubation, the samples were transferred into 
RNA stabilizing TempusTM tubes (Applied Biosystems, Waltham, MA) and stored at -20°C 
until further processing, as per the manufacturer’s instructions. To isolate the RNA, a 
MagMaxTM Core Nuclecic Acid Purification Kit (Applied Biosystems) with a KingFischer 
Flex purification system (Thermo Fisher Scientific) were used 161. Briefly, the TempusTM 
tube content was mixed with 3 mL cold DPBS, the mixture was centrifuged (3000g, 4°C, 
30min) and the supernatant was discarded. The pellets were solubilized in viral lysis buffer 
(600 µL; Invitrogen) and the mixture was transferred to 96-well plates for further RNA 
extraction using the MagMaxTM Kit (Applied Biosystems; 500 µL/sample of wash buffer 
1 and 2, 350 µL/sample binding buffer, 10 µL/sample of beads, 50 µL/ sample of elution 




diluted in 55µL RNAse-free H2O. RT-qPCR and subsequent data processing was 
performed as described under 2.4.2  Monocyte cytokine and receptor gene expression. The 
same primer and probe sets were used with β-gus as the reference gene. The efficiencies 
ranged from 70-83% and are listed in supplemental table 5.3. 
5.3.6 Statistical  analysis 
Data was analyzed and illustrated with R version 4.0.4 82. Age group differences in 
gene expression, monocyte phagocytosis, and TNFα protein production were determined 
using the “lsmeans” function of the “emmeans” package 162 on linear mixed effects models 
163 with horse included as a random effect, and age group, incubation duration and, where 
applicable, LPS dose, as interacting explanatory variables. A second set of models was run 
with BCS included as a covariate as adiposity may influence monocyte function 56. 
Comparisons between age-groups were carried out for each incubation duration, and where 
applicable, within each LPS dose. Confidence intervals (95%-CIs) were calculated for 
significant differences between the age groups.  
Model data was visually inspected for homoscedasticity and normal distribution of 
residuals. If deviations occurred, the response variable was natural logarithm (ln)-
transformed. Ln-transformed data was also plotted in the corresponding figures.  
Because the data contained various outliers, but the sample size of this study was 
small, an outlier capping approach was used rather than outlier exclusion. Outliers, defined 
as data points >1.5 inter quartile ranges above or below the 75th and 25th percentiles, 




for data from the young adult and old horses at each incubation duration, and, where 
applicable, for each LPS dose, separately.  
Results were considered statistically significant at P ≤0.05 and trending at P= 0.06-
0.10. Trends were reported due to the low sample size of this study (n= 14 horses).  
 Results  
5.4.1 Monocyte function 
5.4.1.1 Monocyte E. coli phagocytosis capacity 
The percentage of monocytes that phagocytosed E. coli after 2h and 6h of 
incubation did not differ significantly between old and young adult horses in the BCS-
unadjusted model (Figure 5.3A; Table 5.2); although there was a trend (P= 0.07) for a 
higher percentage of E. coli-positive monocytes in the young adult group after 2h of 
incubation compared to old (Table 5.2). When the model was adjusted for the horses’ BCS, 
the difference in percentage of E. coli-positive monocytes post 2h of incubation became 
statistically significant (P= 0.04; estimated mean difference between groups [EMD]= -
6.22; 95%-CI= -11.88, -0.55; Table 5.2). 
The MFI ratios, an indicator of the E. coli update per monocyte, did not differ 
significantly between the age groups in the BCS-adjusted or in the unadjusted model 
(Figure 5.3B; Table 5.2). 
5.4.1.2 Monocyte TNFα responses to LPS 
The percentage of TNFα-positive monocytes after stimulation with LPS was not 




(Figure 5.4A, Table 5.3). This was found for all incubation conditions, i.e., incubation with 
L-LPS or H-LPS and for 2h or 6h (Figure 5.4A, Table 5.3), and for both the BCS-adjusted 
and unadjusted models (Table 5.3). Similarly, the TNFα MFIs, an indicator of the TNFα 
production per monocyte, did not differ significantly between the age groups (Figure 5.4B, 
Table 5.3), in both the BCS-adjusted and unadjusted models, although a trend (P= 0.10) 
for higher MFIs in the young adult group after monocyte stimulation with H-LPS for 6h 
was observed in the BCS-adjusted model (Table 5.3).  
5.4.1.3 Monocyte cytokine and LPS-receptor gene expression responses to LPS 
Figure 5.5 (A-I) illustrates the gene expression in LPS stimulated PBMCs from 
young adult and old horses, and Table 5.4 shows the results for the comparison of gene 
expressions between the age groups. IL-1β expression was significantly higher in old 
compared to young adult old horses after 2h incubation with L-LPS in the BCS-unadjusted 
model (EMD=15.59, 95%-CI= 5.88 - 25.31, P<0.01; Table 5.4; Figure 5.5C) and in the 
BCS-adjusted model (EMD= 14.11, 95%-CI= 2.57- 25.64, P= 0.02). In addition, there was 
a trend for higher CCL-5 gene expression in PBMCs from old horses post incubation with 
L-LPS for 2h in both the BCS-adjusted and unadjusted models (P=0.09 for both, Table 5.4; 
Figure 5.5B). No significant or trending differences in gene expressions were observed 
between the age groups in PBMCs incubated for 6h with L-LPS (Table 5.4). 
In PBMCs incubated for 2h or 6h with H-LPS, no significant differences in gene 
expression were found between the young adult and old groups, however several trends 
were identified (Table 5.4). IL-1β tended to be higher in old compared to young adult horse 
PBMCs post incubation with H-LPS for 2h in the BCS-unadjusted model (P= 0.07, Table 




adult horses incubated with H-LPS for 2h in the BCS-unadjusted model (P=0.09, Table 
5.4; Figure 5.5I). After incubation with H-LPS for 6h, the expression of IL-6 tended to be 
higher in PBMCs from old horses (BCS-unadjusted model, P=0.10, Table 5.4; Figure 
5.5D), and the expression of TLR-4 tended to be higher in PBMCs from old horses in the 
BCS-adjusted model (P=0.10, Table 5.4).  
5.4.2 Whole blood cytokine and LPS-receptor gene expression responses to LPS 
Figure 5.6 (A-I) illustrates the gene expression in young adult and old horse whole 
blood samples stimulated with LPS and Table 5.5 shows the results of the gene expression 
comparisons between the age groups. The gene expression of IL-8 tended to be lower in 
old-horse whole blood samples after 6h of incubation with L-LPS in the BCS unadjusted 
model (P=0.10, Table 5.5; Figure 5.6E), and this difference became significant in the BCS 
adjusted model (fold difference between groups [reported as data was analyzed on log 
scale]= 0.37; 95%-CI= 0.16, 0.87; P= 0.03; Table 5.5). In addition, the expression of TLR-
4 tended to be lower in whole blood from old horses after 6h of incubation with L-LPS 
(BCS-adjusted model, P=0.09, Table 5.5). The gene expression of IL-6 tended to be lower 
in samples from old horses incubated with H-LPS for 2h compared to young adult-horse 
samples in the unadjusted model (P=0.08, Table 5.5; Figure 5.6D), and this difference 
became significant in the BCS-adjusted model (EMD= -4.04, 95%-CI= -7.76, -0.32, P= 
0.04, Table 5.5). No further genes were found to be differentially expressed between the 




 Discussion  
This study compared monocytes from young adult and old horses concerning 
phagocytosis capacity and magnitude of pro-inflammatory cytokine responses to LPS. In 
the BCS-adjusted model, the percentage of E. coli-positive monocytes after a 2h incubation 
was significantly lower in monocytes from old compared to young adult horses, and in 
PBMCs, used as a proxy for isolated monocytes, a significantly higher IL-1β expression 
was seen in the old compared to the young adult group after a 2h incubation with a low 
dose of LPS (L-LPS; 0.01 µg/mL). Pro-inflammatory cytokine expression was also 
compared between young adult and old horses in LPS stimulated whole blood samples, 
and a significantly lower gene expression of IL-8 (6h incubation with L-LPS) and of IL-6 
(2h incubation with 1µg/mL LPS [H-LPS]) was found in the old group in the BCS-adjusted 
model.   
The percentage of monocytes that phagocytosed E. coli after 2h of incubation tended 
to be lower in monocytes from old horses in the unadjusted model, and the age-group 
difference became significant in the BCS-adjusted model. An age-related reduction in the 
proportion of monocytes that phagocytosed E. coli, or other targets, has also been shown 
in humans 62,154. The reduced frequency of old horse monocytes engaging in phagocytosis 
after 2h, might indicate reduced pathogen clearance during the early hours of an infection 
which could result in an increased pathogen burden. This burden might, however, be 
mitigated through elevated pathogen uptake by individual monocytes, as the mean MFI 
ratio for E. coli phagocytosis appeared to be increased in the old compared to the young 
adult group, although this difference was not significant nor trending. In addition, it should 




using dead E. coli. Differences in phagocytosis between live and dead bacteria are possible, 
as well as between different types of bacteria, and it is likely that the abundance of certain 
blood components, such as antibodies and complement, affect/modulate phagocytosis in 
vivo 156. Therefore, further study of monocyte phagocytosis in old horses would be 
beneficial to provide a context for the findings in this present work which demonstrated an 
age-related monocyte intrinsic dysfunction. Future studies may measure monocyte 
phagocytosis in whole blood samples as in Hearps, et al. 62, comparing the use of dead and 
live bacteria, and different types of bacteria. In addition, efferocytosis might be studied to 
elucidate if this function is reduced in monocytes of old horses and contributing to 
inflamm-aging, as suggested for humans 149,154.  
PBCMs from old horses showed a significantly increased IL-1β gene expression after 
2h of incubation with L-LPS in the BCS-adjusted and the unadjusted models. In addition, 
a trend to higher IL-1β gene expression was found in the BCS-unadjusted model after 2h 
incubation with H-LPS. These findings could indicate a heightened, or a delayed IL-1β 
response to LPS by monocytes of old horses. Confirmation that the differences seen at the 
mRNA level also translate into IL-1β protein production is, however, important to assess 
if the IL-1β gene expression pattern could have implications for horse health. IL-1β has 
important functions in fever regulation, lymphocyte and macrophage activation 153 which 
may be altered in older horses during infection with Gram-negative bacteria.  
In addition, the elevated IL-1β production in response to LPS might represent a novel 
indicator of the inflamm-aging processes in horses. Thus far, inflamm-aging in monocytes 
and lymphocytes has been mainly characterized in terms of significantly elevated 




Elevated IL-1β gene expression post stimulation with LPS might be an additional marker 
of monocyte inflamm-aging in this regard.  
While IL-1β was the only cytokine that was significantly differentially expressed in 
PBMCs between the age groups, trends for increased CCL-5, IL-1β, and IL-6 expression 
in PBMCs of old horses were observed. This finding of a trend to an age-related increase 
in pro-inflammatory cytokine expression in LPS stimulated PBMCs is in accordance with 
the results of a previous equine study reporting non-significant trends as well 66. It is 
possible that both this and the previous study were underpowered to detect significant age 
effects. While Hansen, et al. 66 studied 55 horses, few were ≥20 years of age,  and in the 
present work only 14 horses were enrolled. Significant differences in the gene expression 
patterns between young and old horses might become apparent in a study with larger 
sample size.  
Interestingly, while the production of pro-inflammatory cytokines in response to LPS 
was generally higher in old compared to young adult horse PBMCs, the pro-inflammatory 
responses of whole-blood samples to LPS were generally lower in old than in young adult 
samples. The expression of IL-8 (6h incubation with L-LPS) and of IL-6 (2h incubation 
with H-LPS) was found significantly reduced in old horse samples in the BCS-adjusted 
models, and these differences were trending in the unadjusted models. Reduced pro-
inflammatory cytokine production was also reported for LPS-stimulated whole blood 
samples from elderly people 164. The differences between PBMCs and whole blood samples 
might have various origins. Most importantly, whole blood samples contain, besides 
monocytes, also other innate immune cells, such as neutrophils, which can mount pro-




a component important for shuttling LPS to CD-14 151,152, as well as soluble CD-14 which 
has been shown to modulate the proinflammatory cytokine response of PBMCs to LPS in 
horses 166. All these factors could have contributed to the reduced inflammatory cytokine 
response to LPS seen in whole blood samples of the old horses. If these reduced gene 
expressions translate into reduced pro-inflammatory cytokine protein production, 
implications for the immune response of old horses to endotoxemia or Gram-negative 
bacteria infection are possible.  
The expressions of TLR-4 and CD-14 were quantified in LPS stimulated PBMCs 
and whole blood samples in this study. While no significant differences between the age 
groups were found for the expression of these receptors, a trend for elevated TLR-4 
expression in PBMCs of old horses was noted (6h, H-LPS, BCS-adjusted model), as well 
as a trend for lower TLR-4 expression in whole blood samples of old horses (6h, L-LPS, 
BCS-adjusted model). These trends mimicked the trends of increased and reduced 
inflammatory cytokine gene expression in PBMCs and whole blood samples, respectively. 
This finding might indicate that TLR-4 abundance could play a role in the pro-
inflammatory cytokine response to LPS in old horses.  
In this study, adjusting models for body fat, quantified as BCS, revealed various 
significant differences in pro-inflammatory responses to LPS in whole blood and the 
phagocytosis capacity of monocytes between young adult and old horses that were not seen 
in the unadjusted models. In a previous study in old horses, Adams, et al. 56 found an 
association between changes in body fat and the frequency of monocytes responding with 
TNFα production to PMA/ionomycin stimulation. Together these findings suggest that 




Monocyte pro-inflammatory responses were examined by stimulating PBMCs with 
LPS. While the responses to LPS in PBMCs were expected to originate predominantly 
from monocytes, minor granulocyte contaminations of the PBMC preparations cannot be 
excluded. In addition, isolated human monocytes appear to respond with a slightly different 
pro-inflammatory cytokine profile to LPS stimulation than PBMCs, as can be derived from 
the illustrations in Schildberger, et al. 167. While data on differences in LPS response 
between PBMCs and monocytes are, to the authors knowledge, not available for horses, 
deviations in gene expression patterns are possible, which could originate from the 
monocyte isolation protocol, seeding densities, as well as intercellular communication. 
Exploring monocyte pro-inflammatory function in whole-blood samples, as in Hearps, et 
al. 62, may provide insight into in vivo functions, while the data of this present work 
indicated age-related monocyte intrinsic changes in the LPS response.   
This study had limitations that should be considered when interpreting the findings. 
Firstly, because horses were housed on two farms, a location effect was possible.   
However, the farms were in proximity (linear distance 23km) and management conditions 
were identical, therefore farm effect was expected to be negligible. Secondly, five of the 
young adult horses had to be separated through a fence from their larger herd for safe blood 
collections. This separation could have induced minor stress responses, however, because 
there was no change to the horses’ diet, interaction with the herd through the fence was 
permitted, and horses appeared calm on blood collection days, any effects on measured 
immune functions were expected to be minor. Lastly, this study was limited by small 




Therefore, the findings of this study should be interpreted and applied to the general horse 
population with caution.  
 Conclusion  
The results of this study suggest that the phagocytic function of monocytes as well as 
the monocyte IL-1β response to LPS stimulation may be altered in old horses. In addition, 
this data indicates a reduced IL-8 and IL-6 gene expression in LPS-stimulated whole blood 
samples from old horses. These findings might have implications for senior horse health 
and warrant further investigation. While it was not a goal of this study to determine the 
effect of body condition on monocyte and innate immune cell functions, adjusting the 
statistical models for body condition scores (BCS) revealed significant differences between 
the age-groups that were not seen in the unadjusted models, suggesting that adiposity might 




Table 5.1 Body condition and muscle atrophy ratings.  
Medians and ranges for muscle atrophy scores (MAS) and body condition scores (BCS) 
are shown and statistical differences between young adult and old horses were determined 
using a two-sample t-tests for BCS data and a Fisher’s exact test for MAS data. BCS data 
was natural logarithm (ln)-transformed for analysis. BCS and MAS corresponding to 
sample collection days 1 and 2 were recorded prior to collection 1 and BCS and MAS 
corresponding to sample collection 3 were recorded prior to collection 3 (see Figure 5.1. 
Study design). Only data of horses deemed healthy on blood collection days are shown.   




P-values of age 
group 
comparisons 
Sample collection 1    
Sample size n= 6 n= 5  
BCSa 5.50 (5.00 - 7.50) 4.75 (4.00 - 6.50) 0.17 
MASb    
Neck 1.00 (1.00 - 1.00) 1.00 (1.00 - 2.00) 0.18 
Back 1.00 (1.00 - 2.00) 1.50 (1.00 - 1.50) 0.37 
Hind 1.00 (1.00 - 1.50) 2.00 (1.50 - 2.50) 0.07† 
Sample collection 2    
Sample size n= 7 n= 6  
BCSa 5.50 (5.00 - 7.50) 4.50 (3.75 - 6.50) 0.07† 
MASb    
Neck 1.00 (1.00 - 1.00) 1.25 (1.00 - 2.00) 0.07† 
Back 1.00 (1.00 - 2.00) 1.50 (1.00 - 2.00) 0.47 
Hind       1.00 (1.00 - 
1.50) 
2.00 (1.50 - 2.50) 0.02* 
Sample collection 3    
Sample size n= 7 n= 7  
BCSa 5.50 (5.00 - 7.75) 4.00 (3.75 - 6.50) 0.02* 
MASb    
Neck 1.00 (1.00 - 1.50)       2.00 (1.00 - 
2.50) 
0.07† 
Back 1.00 (1.00 - 1.50) 2.00 (1.00 - 2.50) 0.08† 
Hind 1.00 (1.00 - 1.50) 2.00 (1.00 - 3.00) 0.09† 
† Trend (P= 0.06 - 0.10). 
* Significant difference at P ≤0.05. 
a Body condition scores (BCS). Range of scoring scale: 1 [extremely emaciated] – 9 
[extremely fat] 98.  









Table 5.2 Comparison of monocyte E. coli phagocytosis capacity between old (n= 5) and young adult horses (n= 6).  
PBMCs were incubated with Fluor® 488-labled E. coli for 2h or 6h and the %-E. coli+ monocytes and the corresponding MFIs were 
measured using flow cytometry. The results were compared between old and young adult horses for each incubation duration. Two sets 




  EMD P-value EMD P-value 
%-E. coli+ monocytes  none -4.93 0.07† -1.18 0.64 
 BCS -6.22 0.04* -2.47 0.34 
MFI-ratio E. coli phagocytosis none 0.12 0.67 0.42 0.44 
 BCS 0.03 0.93 0.23 0.69 
Abbreviations: EMD; estimated mean difference between old and young adult horses. 
† Trend (P= 0.06 - 0.10).  








Table 5.3 Comparison of TNFα levels in monocytes from old (n=7) and young adult horses (n= 7) after stimulation with LPS.  
PBMCs were incubated with L-LPS (0.01µg/mL) and H-LPS (1µg/mL) for 2h and 6h. Intracellular staining for TNFα was performed 
and the %-TNFα+ monocytes and the corresponding MFIs were recorded using flow cytometry. The results were compared between old 





  2h 6h 2h 6h 
  EMD P-value EMD P-value EMD P-value EMD P-value 
%-TNFα+ monocytes  none 2.17 0.71 2.49 0.67 -0.37 0.95 -1.35 0.82 
 BCS -4.27 0.51 -3.95 0.54 -6.81 0.30 -7.79 0.24 
MFI TNFα protein production none 916 0.58 2343 0.64 650 0.74 -8805 0.30 
 BCS -540 0.77 -2084 0.71 -1082 0.62 -16241 0.10† 
Abbreviations: EMD; estimated mean difference between old and young adult horses. 









Table 5.4 Comparison of cytokine and LPS-receptor gene expression in PBMCs from old and young adult horses after stimulation with 
LPS.  
PBMCs were incubated with L-LPS (0.01µg/mL) and H-LPS (1µg/mL) for 2h and 6h, and gene expression was quantified using RT-
qPCR. The results were compared between old and young adult horses for each incubation duration and LPS dose. The sample size was 
n= 7 old and n= 7 young adult horses for all genes, LPS doses, and incubation durations, except for the CCL-2 expression in PBMCs 
incubated with H-LPS for 6h (n= 6 old and n= 7 young adult horses) and for the expression of CD-14 in PBMCs incubated with H-LPS 












  2h 6h 2h 6h 
  EMD P-value EMD P-value EMD P-value EMD P-value 
Gene          
CCL-2   none -0.13 0.59 0.02 0.93 -0.04 0.88 -0.10 0.71 
 BCS -0.19 0.48 -0.04 0.88 -0.10 0.72 -0.16 0.58 
CCL-5 none 5.79  0.09† 0.63 0.85 4.86 0.15 3.21 0.33 
 BCS 6.59  0.09† 1.43 0.69 5.67 0.14 4.02 0.28 
IL-1β none 15.59    <0.01* 5.59 0.23 8.70  0.07† 6.69 0.16 
 BCS 14.11  0.02* 4.10 0.45 7.21 0.20 5.21 0.34 
IL-6 none 0.33 0.20 0.23 0.37 0.42 0.11 0.43 0.10† 
 BCS 0.14 0.61 0.03 0.90 0.23 0.40 0.24 0.39 
IL-8 none 15.80 0.15 21.10 0.12 19.80 0.19 34.70 0.12 
 BCS 15.70 0.23 20.90 0.20 19.40 0.28 34.30 0.20 
IL-18 none 0.01 0.90 -0.01 0.81 0.04 0.43 -0.05 0.29 
 BCS -0.01 0.86 -0.03 0.61 0.02 0.66 -0.06 0.22 
TNFα  none 0.59 0.29 0.20 0.71 0.70 0.21 0.07 0.89 
 BCS 0.39 0.54 0.01 0.99 0.51 0.43 -0.12 0.85 
TLR-4  none 0.02 0.82 0.09 0.26 0.04 0.56 0.09 0.22 
 BCS 0.06 0.45 0.13 0.12 0.09 0.28 0.14 0.10† 
CD-14 none -6.22 0.19 -0.88 0.85 -8.25 0.09† -1.65 0.74 
 BCS -6.08 0.26 -0.73 0.89 -8.10 0.14 -1.50 0.79 
Abbreviations: EMD; estimated mean difference between old and young adult horses.  
† Trend (P= 0.06 - 0.10). 









Table 5.5 Comparison of cytokine and LPS-receptor gene expression in whole blood from old and young adult horses post stimulation 
with LPS.  
Whole blood samples were incubated with L-LPS (0.01µg/mL) and H-LPS (1µg/mL) for 2h and 6h, and gene expression was quantified 
using RT-qPCR. The results were compared between old and young adult horses for each incubation duration and LPS dose. The sample 












  2h 6h 2h 6h 
  EMD P-value EMD P-value EMD P-value EMD P-value 
Gene          
CCL-2   none -5.03 0.65 -3.45 0.76 -6.75 0.55 -1.54 0.89 
 BCS -7.87 0.53 -6.29 0.62 -9.59 0.45 -4.39 0.73 
CCL-5 none -1.41 0.57 -1.41 0.56 -0.44 0.86 -0.53 0.83 
 BCS -1.80 0.50 -1.81 0.50 -0.84 0.75 -0.92 0.73 
IL-1β none 3.62 0.70 -0.96 0.92 9.32 0.33 1.60 0.86 
 BCS -4.97 0.59 -9.54 0.31 0.74 0.94 -6.98 0.45 
IL-6 none -1.32 0.43 -0.35 0.83 -3.05 0.08† -0.21 0.90 
 BCS -2.31 0.20 -1.33 0.44 -4.04 0.04* -1.19 0.49 
IL-8 none -5.30 0.68 -26.80 0.10† -0.70 0.98 -23.50 0.47 
 BCS -15.80 0.24 -39.60 0.03* -24.60 0.42 -50.10 0.15 
IL-18 none 0.40 0.19 -0.12 0.68 0.12 0.68 -0.35 0.25 
 BCS 0.35 0.32 -0.17 0.61 0.07 0.84 -0.40 0.25 
TNFα  none -0.59 0.44 -0.05 0.36 -0.79 0.58 -0.14 0.22 
 BCS -0.64 0.47 -0.06 0.40 -0.89 0.59 -0.15 0.27 
TLR-4  none 0.07 0.91 -0.81 0.19 0.75 0.22 -0.26 0.66 
 BCS -0.28 0.67 -1.15 0.09† 0.41 0.53 -0.60 0.36 
CD-14 none -0.66 0.53 0.80 0.45 -0.15 0.88 0.29 0.78 
 BCS -0.96 0.40 0.49 0.66 -0.46 0.68 -0.01 0.99 
Abbreviations: EMD; estimated mean difference between old and young adult horses.  
† Trend (P= 0.06 - 0.10). 




Figure 5.1 Study design.  
Blood was collected for monocyte phagocytosis-capacity analysis (Blood-1), 
quantification of receptor and cytokine responses to LPS in whole-blood samples (Blood-
2) and in PBMCs (Blood-3). All horses were assessed twice for body composition, i.e., 
body fat 98 and muscle atrophy40. Evaluation occurred in two groups (n= 8 Oct. 23rd and 
Jan. 13th; and n= 6 Oct. 22nd and Jan. 8th). Samples were collected twice from all horses for 
insulin dysregulation (ID) testing (Endocrine testing-1 and 2) and once form all old horses 






Figure 5.2 Gating strategy to determine monocyte phagocytosis capacity.  
A Forward scatter-height (FSC-H) and sideward scatter-height (SSC-H) profiles were used 
to identify monocytes (R2)56. B Singlet monocytes were selected in R3. C Negative control 
samples were used to set gates for the E. coli negative (R4) and positive (R5) monocyte 
populations. D Extracellular E. coli adhesion was measured in the E.coli positive gate (R5) 
of samples incubated on ice. E Extracellular E. coli adhesion and phagocytosis were 
measured in the E. coli positive gate (R5) of samples incubated at 37°C. The %-monocytes 
that phagocytosed E.coli was calculated by subtracting the %-E. coli+ monocytes recorded 
in samples incubated on ice (R5, image D) from the corresponding (i.e., of same animal) 
%- E. coli+ monocytes recorded in the 37°C samples (R5, image E) 156. MFI-ratios were 
calculated as (E.coli+ monocyte MFI [37°C]) / (corresponding E.coli+ monocyte MFI [ice]) 






Figure 5.3 E. coli phagocytosis by monocytes from young adult and old horses.  
White boxes represent monocytes of old horses (n= 5) and grey boxes those of young adult 
horses (n= 6). Diamonds indicate means. Results of individual horses (black dots) plotted 
with slight random shift to avoid overplotting. A Boxplot of percent E. coli+ monocytes 
after 2h and 6h incubation. B Box plots of MFI-ratios (i.e., MFI of E. coli+ monocytes 






Figure 5.4 TNFα in monocytes from young adult and old horses after incubation with LPS.  
Monocytes were intracellularly stained for TNFα after incubation with a low dose of LPS 
(L-LPS; 0.01µg/mL) or a high dose of LPS (H-LPS; 1µg/mL) for 2h and 6h. White boxes 
represent monocytes from old horses (n= 7), grey boxes those from young adult horses (n= 
7). Black dots indicate results of individual horses which were plotted with slight random 
jitter to avoid overplotting. Diamonds represent means. A Percentage of TNFα+ monocytes 
after incubation with L-LPS or H-LPS for 2h or 6h. B MFIs of TNFα production by 











Figure 5.5 Gene expression in PBMCs from young adult and old horses post incubation with LPS.  
PBMCs were incubated with a low dose of LPS (L-LPS; 0.01µg/mL) or a high dose of LPS (H-LPS; 1µg/mL) for 2h or 6h. Gene 
expression was measured using RT-qPCR and expressed as ΔFD representing background corrected gene expression relative to the 
reference gene. White boxes show old horse samples and grey boxes show young adult horse samples. Black dots indicate results of 
individual horses. Dots were plotted with slight random shift to prevent overplotting. Diamonds represent means. A CCL-2 gene 
expression. B CCL-5 gene expression. C IL-1β gene expression. D IL-6 gene expression. E IL-8 gene expression. F IL-18 gene 
expression. G TNFα gene expression. H TLR-4 gene expression. I CD-14 gene expression. The sample size was n= 7 old and n= 7 
young adult horses for all genes, LPS doses, and incubation durations, except for the CCL-2 expression in PBMCs incubated with H-
LPS for 6h (n= 6 old and n= 7 young adult horses) and for the expression of CD-14 in PBMCs incubated with H-LPS for 6h ( n= 6 old 










Figure 5.6 Gene expression in whole blood from young adult and old horses after incubation with LPS.  
Whole blood was incubated with a low dose of LPS (L-LPS; 0.01µg/mL) or a high dose of LPS (H-LPS; 1µg/mL) for 2h or 6h. Gene 
expression was measured using RT-qPCR and expressed as ΔFD representing background corrected gene expression relative to the 
reference gene. White boxes show old horse samples (n= 6) and grey boxes show young adult horse samples (n= 7). Black dots indicate 
results of individual horses. Dots were plotted with slight random shift to prevent overplotting. Diamonds represent means. A CCL-2 
gene expression. B CCL-5 gene expression. C IL-1β gene expression. D IL-6 gene expression. E IL-8 gene expression. F IL-18 gene 





 CONCLUSIONS AND FUTURE DIRECTIONS 
While the pathology and prevalence of age-related muscle atrophy is comparably well 
understood in people, little research has been undertaken to elucidate these topics in horses. 
In this dissertation, the prevalence, adverse effects of, and risk factors for low muscle mass 
in senior horses were studied and relationships between inflammatory markers and muscle 
mass were explored as a potential mechanism underlying muscle atrophy. To facilitate the 
study of muscle loss, a muscle atrophy scoring system was developed and tested. In 
addition to the study of muscle atrophy, age-related changes in the immune system of 
horses were investigated in this dissertation. While alterations in the function of adaptive 
immune cells have been demonstrated in multiple studies in old horses, much less is 
currently known about the effect of age on innate immune cells, and especially on 
monocytes. Altered monocyte functions may have implications for immune responses to 
vaccination, infection, and the development of inflamm-aging. Thus, this dissertation 
characterized changes in monocyte function in old horses. Senior horses (≥15 years) 
represent up to one-third of the global equine population. In addition, anecdotal evidence 
suggests that more sophisticated veterinary care for older horses has been sought, 
illustrating the relevance of research on such topics as age-related changes in immune 
function and muscle atrophy in senior horses which are at the core of this dissertation.  
A U.S.-wide survey study with owners of senior horses (≥15 years of age) was 
undertaken. This study identified advancing age, the horses’ sex, their primary use type, 
osteoarthritis of the leg joints and pituitary pars intermedia dysfunction as low muscle mass 




increased risk of low muscle mass to be selected for close monitoring. This study further 
showed that the prevalence of low-muscle mass was relatively high, with 1 in 6 senior 
horses affected, and that in the majority (~2/3rd) of affected horses the ability to work, 
and/or welfare-related aspects, such as the ability to get up after lying down, were impaired. 
These findings strongly suggest that further study on low muscle mass and skeletal muscle 
atrophy in senior horses is warranted. Future research may especially focus on modifiable 
sources of muscle atrophy in senior horses and subsequent development of prevention and 
treatment strategies to improve welfare in the senior horse. In elderly people, exercise is 
considered an important modulator of muscle atrophy, which may be explored as a 
treatment or prevention strategy in horses as well.  
Aside from providing insights into low muscle mass in senior horses, the survey study 
also showed that the majority of senior horses still engage in moderate intensity work, and 
that close to one-third of horses used for competition riding still engage in high intensity 
exercise such as galloping and higher-level competition riding or training. As reductions 
in the physiological responses to exercise in old horses have been shown, further research 
into exercise protocols that do not overwhelm senior horses is therefore warranted. This 
aspect may also be considered when exploring exercise prescription for low muscle mass 
in old horses and is of special importance for horses with other underlying health conditions 
that may reduce their capacity to exercise beyond limitations posed by ageing.  
For studies of muscle mass and atrophy in horses, a muscle atrophy scoring system 
was developed and tested by three raters in 38 horses of varying breed, age, and health 
status. Inter-rater agreement on scores of the neck, back and hind region were good to 




indicating that muscle atrophy evaluations of back, neck and hind regions, but not of the 
abdominal region have acceptable reliability. In addition, the system might accurately 
identify horses with muscle atrophy, as higher scores (indicating more atrophy) were 
observed in older horses and those affected by pituitary pars intermedia dysfunction, which 
are horse groups in which muscle atrophy is commonly reported. Nevertheless, the system 
still requires validation for accurate reflection of muscle mass volume in horses, reliable 
detection of muscle mass changes over time, and correct anchoring of the scoring scale to 
confirm that a score of 1 (no atrophy; normal muscle mass) accurately describes horses in 
which muscle mass is normal.  
Relationships between indicators of muscle mass (muscle atrophy scores, estimated 
FFM, and serum creatinine levels) and serum inflammatory markers were explored in 22 
healthy horses. Based on their serum inflammatory maker levels, horses were categorized 
as affected or unaffected by low-grade inflammation, and hind and neck region muscle 
atrophy scores were significantly higher in horses with low-grade inflammation; although 
these differences were no longer significant once the model was adjusted for age. In 
addition, no significant linear associations between muscle mass indicators and 
inflammatory markers were found, however trends to a positive association between serum 
IL-10, IFNγ and hind region muscle atrophy scores were observed. These findings indicate 
that while significant associations between muscle mass and circulating inflammatory 
markers were generally not observed in this study, these associations cannot be excluded, 
which warrants further study of the relationship between inflammation and muscle atrophy 
in senior horses. It should be considered, however, that this study also showed that the 




relatively low, indicating that any contributions of circulating cytokines or CRP to loss of 
muscle mass in healthy senior horses may be minor. To address the shortcomings of this 
present study (i.e., cross-sectional design, small sample size), future studies of larger scale 
and longitudinal design may be conducted, assessing changes in muscle mass and 
inflammatory markers in the same animals over time. In addition, future research may 
investigate the relationships between inflammation and muscle atrophy more directly by 
e.g., administrating low levels of TNFα or other cytokines to adult horses and measuring 
the effects on muscle mass. 
The effect of age on monocyte function was determined by comparing E. coli 
phagocytosis capacity and pro-inflammatory cytokine gene expression responses to LPS 
stimulation between young and old horses. The findings of this study suggest that the 
capacity of old horse monocytes to phagocytose pathogens such as E. coli might be reduced 
and that the IL-1β production in response to LPS might be elevated in senior horses. These 
alterations could have implications for the severity of Gram-negative bacteria infections in 
senior horses, however confirmation of these finding in vivo, or in in vivo-like systems 
(e.g., monocyte phagocytosis measurement in whole blood) is needed. While this study 
demonstrated monocyte intrinsic dysfunctions, these may be compensated for by factors in 
the in vivo environment. This study further suggested that innate immune cell function may 
be affected by adiposity in horses as differences in monocyte function and the cytokine 
responses to whole-blood LPS stimulation between the age groups were often not 
significant until the statistical model was adjusted for body condition scores. Thus, a 




be beneficial to better understand if innate immune dysregulation is present and 
contributing to disease progression and/or the severity of infection.  
In summary, the findings of this dissertation provide first insights into outcomes of, 
prevalence, and risk factors for low muscle mass in senior horses and add to our current 
understanding of age-related changes in the immune system of the horse, as well as to our 
knowledge on relationships between inflammatory markers and muscle mass. The muscle 
atrophy scoring system developed as part of this work might serve equine practitioners and 
horse owners in identifying and monitoring muscle atrophy in horses once further 
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